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ABSTRACT  
Background: Shortened life expectancy may limit older adults’ ability to benefit from certain 
medical interventions, such as preventive services. Appropriate consideration of a patient’s life 
expectancy may help physicians weigh potential benefits against potential harms for that 
individual. Some recent cancer screening guidelines have recommended this individualized 
approach to cancer screening decisions to avoid overscreening or underscreening. However, it 
is not clear how competent physicians are at predicting life expectancy, and there is little 
consensus about how these predictions should guide their recommendations for or against 
cancer screening.  
Purpose: This systematic review attempts to characterize physicians’ accuracy and reliability at 
predicting the life expectancy of older adult outpatients. A discussion further considers what 
level of evidence is needed to justify the replacement of an age-based cancer screening 
guideline to a life expectancy guideline for stopping cancer screening. 
Data Sources: MEDLINE, EMBASE, PsycINFO, reference lists 
Study Selection: Studies that assess physicians’ estimates of life expectancy for older adults 
who are not terminally ill are included.  
Data Extraction: Data relating to physicians’ accuracy and reliability, as well as physician 
attributes associated with predictive performance, are extracted. Study quality is assessed 
according to criteria adapted from the Centre for Review and Dissemination’s quality 
assessment criteria for diagnostic tests. 
Data Synthesis: Six small, cross-sectional studies utilizing patient vignettes and comparing 
physicians’ predictions to some reference standard are included. As a group, physicians have a 
tendency to underestimate life expectancy by 1–2 years and 10-year mortality risk by 10-15%, 
with poor inter-rater reliability. Among studies that reported LE predictions in years (n = 3), the 
prediction error (±SD) ranged from -1.63 (± 3.70) years to +0.34 (± 3.29) years.  
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Limitations: Quality ratings for included studies were generally fair or poor. Major limitations 
include the use of patient vignettes in place of real patient encounters, reference standards for 
life expectancy of unclear quality, and small, nonrandom samples of physicians. 
Conclusions: As a group, physicians are moderately accurate in their predictive ability for the 
life expectancy of older adults but reliability among individuals is poor. Larger studies of 
physicians’ predictions for real patients are needed, possibly incorporating life expectancy 
prediction rules to assist physicians. Six criteria for evaluating whether there is enough evidence 
to support a life expectancy-based cancer screening guideline are proposed. 
 
INTRODUCTION 
 
Knowledge of a patient’s prognosis, including life expectancy, is helpful in many clinical 
decision-making scenarios.1, 2 These scenarios range from decisions about how aggressively to 
manage a patient’s known disease, to how tightly to control risk factors for future disease, and 
importantly, whether or not to use clinical preventive services, such as cancer screening. In the 
case of cancer screening, the mortality benefits of the screening intervention may take years to 
be appreciated, while the harms of the intervention may be felt much sooner. Knowledge of a 
patient’s life expectancy, especially an elderly patient who may have years rather than decades 
of life remaining, may help providers balance the likelihood of benefit against the likelihood of 
harm for a particular patient. 
Various tools for predicting a patient’s life expectancy are available to health care 
providers. Actuarial data in the form of life tables are available for large populations, and may 
report average years of life remaining for individuals of various ages, as well as the range of 
years remaining over quartiles of health.1 The life insurance and health insurance industries 
have developed various risk calculators to adjust these population average life expectancies for 
individual risk factors, based on client data and medical literature.3 In recent years, investigators 
in the medical field have developed their own prediction rules for life expectancy derived from 
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prospective studies of patient cohorts, taking into account patient data such as comorbidities, 
functional status, and biometrics. A high-quality systematic review of prediction rules for all-
cause mortality in older adults was recently published,2 and the authors published a useful 
website (www.eprognosis.org) summarizing the prediction rules they found as a resource for 
clinicians.4 
In practice, when physicians are making cancer screening decisions with patients, they 
may not have immediate access to actuarial data or prediction rules for life expectancy, but rely 
on some understanding of these data and their clinical experience. While a growing body of 
literature describes physicians’ poor performance at predicting the life expectancy of terminally 
ill patient groups,5-10 there is less evidence for their predictive performance for general 
populations of older adults. The goal of this is systematic review is to summarize the literature 
on the accuracy and reliability with which physicians estimate the life expectancy of older adults 
in outpatient settings. Accuracy refers to the nearness of the physicians’ predictions to a 
reference standard for life expectancy. Reliability, or precision, refers to the agreement among 
different predictions for the same patient. Inter-rater reliability describes the agreement among 
multiple physicians making predictions for the same patient (poor reliability means a high 
degree of variation among their predictions). Intra-rater reliability describes the agreement 
between two or more predictions made by the same physician for the same patient, on different 
occasions. 
Life expectancy and cancer screening 
Prognosis is important in the case of cancer screening because many years must pass 
before a patient may experience benefit from screening, a concept sometimes referred to as 
“lag time,”11-13 while harms may be experienced immediately. Net benefit is defined as benefits 
minus harms, and the likelihood of net benefit therefore depends on a patient’s life expectancy 
in addition to other factors such as test characteristics and the benefits of early treatment. 
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The benefits of screening are generally measured as reduction in cancer-specific 
mortality, expressed as lives extended divided by number of individuals screened over a certain 
period of time. A full complement of potential benefits, however, may include other physical, 
psychological, or financial effects of screening, such as reassurance in a patient who screens 
negative, or avoidance of cancer-related symptoms through early treatment. 
The potential harms of screening are more diverse and may result from any element of 
the “screening cascade,” which includes initial screening, work-up of abnormal or inconclusive 
results including false positives, and the management of detected lesions. These harms may 
include emotional concern or distress, bodily harm, hassle, financial drain, or opportunity cost 
resulting from the screening cascade. They may be experienced in the short term or the long 
term.14 Choosing the example of breast cancer screening, key harms may include pain and 
radiation exposure during mammography, anxiety due to false positive imaging, pain or scar 
due to biopsy, psychological effects of diagnosing a patient with cancer including overdiagnosis, 
physical and psychological effects of breast cancer treatment, and hassle and costs associated 
with all these steps.  
Special considerations for cancer screening in older adults  
 
Attention to the balance of benefits and harms for cancer screening is particularly 
pertinent for older adults. With increasing age, both the benefits and harms of screening are 
understood to shift in complex ways.1, 12, 13, 15 An individual’s overall risk of death from cancer 
increases with age; however, the benefit of cancer screening decreases with decreasing life 
expectancy.1 The accuracy of screening tests may change with age; for instance, the sensitivity 
of sigmoidoscopy for colorectal cancer may decrease with age because the absolute risk of 
right-sided cancer increases, while the sensitivity of mammography increases with age because 
slow-growing cancers become more prevalent.13 The harms associated with screening, work-up, 
and treatment may also increase with age and age-related comorbidities such as dementia.13161 
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For individual patients, a time will come when the overall harms of screening equal or outweigh 
the overall benefits; in other words, the net benefit of screening becomes zero or negative. 
Deciding when to stop cancer screening in older adults is a challenge. The simplest 
predictor of a patient’s prognosis is her age, and cancer screening guidelines have traditionally 
used age-based thresholds to indicate when to stop screening.17 In recent years, however, there 
has been a movement toward individualized decision making involving patients, including 
consideration of their age and individual prognostic factors when making cancer screening 
decisions1, 2, 1816. Screening guidelines have adapted to this trend in different ways. Some 
guidelines recommend that cancer screening be restricted to individuals with life expectancy 
greater than a certain number of years, such as five years, and others make reference to life 
expectancy or comorbidity without specification as to number of years. The choice of a life 
expectancy threshold in years is generally based on the separation of survival curves for 
screened and unscreened populations,17 but is a very nuanced choice that I will discussed later 
in this paper. Table 1 presents four example breast cancer screening guidelines from prominent 
panels and professional organizations. 
Organization Breast Cancer Screening Recommendation 
US Preventive 
Services Task Force 
≥ 75 yrs: Insufficient evidence to balance the benefits and harms of the 
service19 (2009) 
"[T]he evidence [for mammography] is also generalizable to women 
aged 70 and older...if their life expectancy is not compromised by 
comorbid disease20" (2002) 
American Cancer 
Society 
No upper age limit. 
“[I]f an individual has an estimated life expectancy of less than three to 
five years, severe functional limitations, and/or multiple or severe 
comorbidities likely to limit life expectancy, it may be appropriate to 
consider cessation of screening21” (2003) 
American Geriatrics 
Society 
Continue screening older women who have a life expectancy >= 4 
years22 (2000)  
American College of 
Obstetricians and 
Gynecologists 
No upper age limit. 
“Medical comorbidity and life expectancy should be considered in a 
breast cancer screening program for women aged 75 years or older”23 
(2011)  
Table 1. Guidelines – When to Stop Breast Cancer Screening in Older Women 
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Current practice of cancer screening in older adults 
 Actual cancer screening practices for older adults in the United States are 
heterogeneous. One way they can be described is by rates of screening in age-eligible 
populations. One recent study24 examined cancer screening in racially diverse older adults 
through the National Health Interview Survey, an annual, in-person survey of health trends. The 
authors analyzed self-reported screening among 1697 adults in the 75-79 age group and 2376 
adults in the ≥80 age group, as well as younger adults. Screening was reported as having 
received an appropriate cancer-specific screening test within the past number of years 
described as an appropriate screening interval by the US Preventive Services Task Force (e.g., 
fecal occult blood testing within one year, sigmoidoscopy within five years, or colonoscopy 
within ten years). Screening prevalence declined with age, but remained high even in the oldest 
age group. Among adults aged 75 to 79, they were 62% for breast cancer, 57% for colorectal 
cancer, 57% for prostate cancer, and 53% for cervical cancer. Among adults aged 80 or older, 
the rates declined to 50% for breast, 47% for colorectal, 42% for prostate, and 38% for cervical. 
No association was found between cancer screening and number of self-reported comorbidities 
except in the case of prostate cancer, for which one or more comorbidities was associated with 
a higher rate of prostate specific antigen (PSA) screening, possibly due to increased 
interactions with health care leading to increased opportunities for screening in this group. 
Although there are limitations to their reliance on self report, the authors appropriately speculate 
that the high screening rates among older adults may reflect the performance of screening 
without full consideration of risks and benefits. Unfortunately, such population-based statistics 
are limited because they cannot tell us about the appropriateness of screening decisions for 
individual patients. According to 2007 U.S. Life Tables,25 the average life expectancy of an 80 
y.o. woman, the youngest in the ≥80 age group, is 9 years. The average woman in the ≥80 age 
group is likely older than 80 and has a more limited life expectancy. The finding that half (50%) 
of such women were screened for breast cancer suggests that some women were screened 
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who would not be expected to live long enough to benefit from the cancer screening. However, 
analysis of this data cannot define prognostic information available at the time the screening 
decision was made. 
 There is some additional evidence from population studies that groups of patients who 
are unable to benefit from cancer screening are being screened. One study26 of mammography 
based on Medicare claims in women with and without dementia estimates that nationally, 
120,000 screening mammograms were performed on women with severe cognitive impairment 
in 2002, despite this group’s median survival of 3.3 years. Another study27 of women undergoing 
dialysis for end stage renal disease found that, despite a low (25%) overall rate of biennial 
screening mammography in this group, 13% of women who died within five years from the start 
of the study were screened. One prospective study28 of Medicare patients with advanced cancer 
found that, despite their poor prognosis, 9% of women received mammograms, 6% received 
Papanicolaou tests, and 15% of men received PSA tests. Other studies have further 
documented overscreening in terms of inappropriate frequency of screening29 or inappropriate 
consideration of medical history (e.g., cervical cancer screening in women without a cervix30).  
At the same time, there may also be older adults in excellent health for whom the 
benefits of screening outweigh the harms, but are not being screened. In one prospective 
study12 of veterans over age 70, 47% of patients with no comorbidities who had life 
expectancies greater than 5 years were not screened for colorectal cancer. Another study31 on 
self-reported mammography in Medicare patients found that 22% of women with good 5-year 
prognosis (mortality risk ≤ 10%) had not been screened in the past 2 years, and that screening 
rate was further associated with wealth, regardless of prognosis.  
These studies of screening rates provide some evidence of both underscreening and 
overscreening, but are nonetheless unable to illuminate how screening decisions are being 
made at the level of the physician and patient. A few small studies have examined this decision 
making, and find that physicians generally report practicing individualized decision making 
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considering patients’ prognosis and other factors. One qualitative study32 interviewed 16 
physicians at a large academic center about how they counsel women older than 80 about 
screening mammography. All of the physicians mentioned that the patient’s health and 
functional status influenced the screening decision, and half reported that they stopped 
recommending or recommended against screening women they perceived to have low life 
expectancy. Other themes that emerged were the discomfort of broaching the issue of stopping 
screening with patients, the difficulty of explaining the potential harms of screening, and clinical 
uncertainty about the harms and benefits of screening older women. Another qualitative study33 
interviewed fifteen primary care physicians in community practices about their decisions to 
continue or stop colorectal cancer screening in elderly patients. Physicians in the study report 
considering numerous factors in the screening decision process and practicing shared decision 
making in cases of clinical uncertainty. Clinical factors of importance to the physicians included 
age, functional status, and estimated life expectancy of 5 or 10 years. Physicians emphasized 
uncertainty about life expectancy as well as the large number of factors influencing the 
screening decision as sources of difficulty. Individual patient factors such as personality and 
previous screening behavior became more important when there was uncertainty about the 
patient’s clinical prognosis. 
Definitions 
It is helpful to define some terms for this review. Prognosis is a general term that refers 
to the probability of an individual developing a certain outcome, such as death, over a specific 
period of time.18 Life expectancy (LE) falls under the umbrella of prognosis, and may be defined 
as the average number of years an individual of a given age is expected to live if current 
mortality rates apply.3 Therefore, a predicted life expectancy may be compared against the best 
actuarial or epidemiological data available, which are often stratified by age, gender, and 
country, and may be further stratified by comorbidity or other factors such as quartiles of 
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longevity for each age. Mortality risk reflects a patient’s probability of death within a certain 
number of years; for instance, a 10-year mortality risk of 50% means that a patient has a 50% 
chance of dying within 10 years. While they provide different types of information about a 
patient’s prognosis, both life expectancy and mortality risk are useful when it comes to clinical 
decisions. Mortality risk may in fact be the more helpful statistic for cancer screening decision 
because it helps physicians consider a patient’s likelihood of surviving past a certain threshold 
necessary to reap net potential benefit from screening. 
Key Question 
How accurate and reliable are physicians at predicting the life expectancy of older adults in the 
outpatient setting? 
METHODS 
Data Sources and Searches 
 I searched MEDLINE, EMBASE, and PsycINFO from inception through April 22, 2012 
for relevant studies addressing this key question. I used the MeSH search terms “Life 
Expectancy,” “Forecasting,” “Prognosis,” “Outpatients,” and “Nursing Homes,” along with other 
relevant key words. Complete search strategies for each database are listed in Appendix A. I 
also hand searched the bibliographies of all relevant studies identified through these searches, 
as well as other related literature, and used Google Scholar to search for articles that cited my 
included studies. I finally used MEDLINE’s related articles search feature for included studies in 
attempt to identify additional studies. I did not attempt to search for studies not published in 
peer-reviewed journals. A librarian specialist in health sciences provided guidance for this 
search strategy. 
Study Selection 
 Studies identified by database and hand searches were reviewed by the present author 
only. A flow diagram of the study selection process is reported in the results section. I first 
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reviewed the titles and abstracts of all studies and excluded those that did not match inclusion 
criteria. If it was not clear from the abstract whether the study met criteria, I reviewed the full text.  
 Inclusion criteria are outlined by the PICOTTS method in Table 2.  
 
Table 2. PICOTTS framework. 
 Population Physicians, including resident physicians 
- Generalists or specialists 
“Intervention” 
(Assessment) 
Assessment of physicians’ ability to predict the absolute life expectancy 
or all-cause mortality risk of non-hospitalized older adults (age >= 50) 
- Require that average life expectancy prediction be >= 1 yr 
Comparator One of the following: 
- Patient’s actual remaining years/months of life 
- Life expectancy from actuarial data such as life tables, with or without 
further statistical manipulation based on comorbidity or other factors 
Outcomes Primary outcomes:  
- Accuracy (agreement between predictions and a reference standard) 
and reliability (intra-observer and inter-observer reliability) of physician-
predicted life expectancy vs. comparator 
Secondary outcomes:  
- Provider attributes associated with predictive performance 
Time allowed for 
outcomes to appear 
Any 
Time over which 
literature searched 
Inception of MEDLINE, EMBASE, and PsycINFO to April 22, 2012 
Setting Outpatient  clinics and nursing homes; any setting for delivery of paper-
based patient vignettes 
Study designs 
allowed 
Cohort studies, cross-sectional studies, patient vignette-based studies 
 
 
Rationale for Eligibility Criteria 
I chose to include all study designs to keep my search as broad as possible. The study 
designs of highest relevance to this review are cross-sectional studies, prospective cohort 
studies, and/or clinical trials of life expectancy prediction. Although this review is primarily 
interested in life expectancy predictions made in the primary care setting where cancer 
screening happens, I chose to include all physicians to keep the scope of my search broad. I 
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hypothesized that providers’ understanding of patient prognosis comes from their training and 
clinical experience with elderly patients, which may not be dissimilar across medical specialties. 
I also expected that data for primary care providers may be very limited.  
I established the following exclusion criteria: 
 Prediction of single-cause mortality (e.g., predicting years to death from breast cancer). 
A patient’s probability of benefit from cancer screening depends on the likelihood that a 
certain cancer will kill her before another cause of death does. Therefore, I am only 
interested in a patient’s life expectancy with regard to all-cause mortality. 
 Prediction in populations with terminal illness or other advanced disease (average 
predicted LE <= 1 year) who would not be screened for cancer by a reasonable 
physician. One may wonder whether a provider’s ability to predict life expectancy over a 
short period of time may correlate with her ability to predict life expectancy over a longer 
period of time among healthier adults. For instance, if providers perform poorly at 
predicting life expectancy in short-term clinical scenarios, may we assume they perform 
as poorly or worse at predictions over longer periods of time? I have decided it is not 
reasonable to assume that short-term predictions may function as a proxy for long-term 
predictions, which are influenced by different factors. 
 Study setting in an underdeveloped country, where the average life expectancy and 
major causes of death may differ greatly from the United States. 
 Non-English study. 
Data Extraction and Quality Assessment 
 I collected results from included studies in a standardized way in Table 3. Whenever 
possible, I abstracted results on prediction performance for licensed providers (including 
resident physicians) from other subjects such as medical students, nurses, and other medical 
personnel. I successfully to contacted the authors of 2 studies34, 35 and obtained additional data 
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on physician performance. I did not attempt to contact the authors of other studies. I assessed 
the quality of included studies in a systematic way using criteria adapted from The Centre for 
Reviews and Dissemination’s quality assessment criteria for diagnostic tests (CRD Monograph 
Table 2.1).36 These criteria are in turn adapted from a study of sources of bias (internal validity) 
and variation (external validity) in studies of diagnostic accuracy conducted by Whiting and 
colleagues, 2004.37 Using this approach, I considered clinicians’ estimation of life expectancy or 
mortality risk as a type of diagnostic “test,” and the actuarial data their predictions were 
compared against as the “reference standard.” A sample quality assessment form including 
descriptions of potential quality problems is shown in Table 3. I did not develop specific 
definitions for the final ratings of internal validity and external validity, but based these on the 
sum of evidence listed in each form. Quality assessment forms for each included study are 
included in Appendix B. 
 
Table 3. Sample Quality Assessment Form (adapted from CRD Monograph Table 2.136) 
Study citation:  
 
Area of potential 
quality problem 
Internal or 
External 
Validity? 
Description of potential problems 
Patient Vignette/Assessment Characteristics  
Patient demographics External validity Clinicians’ ability to predict LE may depend on the patient 
population (e.g., age group, types of comorbidities). 
Exclusion of certain groups (e.g., patients over 90 y.o.) will 
limit applicability. 
Prevalence, severity 
of patient 
comorbidities 
External validity, 
Internal validity 
Prevalence and severity of comorbidities may affect 
prediction performance. 
In settings of higher prevalence of comorbidities, clinicans 
may be more prone to classify LE as especially high or 
especially low (context bias). 
Level of detail of 
vignettes 
External validity Differences between patient details included in vignettes 
and those encountered in real life will limit applicability. 
Format of paper quiz vs. real human encounter will also 
limit applicability. 
Number of patients 
represented 
Internal validity Few patient vignettes will limit accuracy and precision of 
outcomes. 
Choice and Application of Reference Standard for LE (e.g., actuarial LE) 
Appropriateness of 
reference standard 
Internal validity Difference between years of life predicted by the reference 
standard and reality (validity of reference standard) may 
lead to underestimation or overestimation of clinicians’ 
performance. 
Sophistication of Internal validity Degree to which reference standard accounts for patient 
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reference standard characteristics such as comorbidity affects its validity. 
Clinician recruitment, characteristics 
Sample size of 
clinicians 
Internal validity Small sample size will limit power of study. 
Subject selection External validity Identification and appropriate sampling of source 
population for subjects affect applicability. Potential 
subjects who refuse participation or do not complete 
assessment should be noted. 
Clinician 
characteristics 
External validity Different clinician groups will have different performance 
characteristics. 
Assessment Methods 
Assessment 
administration 
Internal validity, 
External validity 
Manner of assessment delivery (e.g. relaxed vs. hectic 
environment, timed or untimed) affects external validity. 
Differential access to resources during assessment (e.g., 
“cheating” among subjects) affects internal validity. 
Overall potential for 
measurement bias 
Internal validity (low/moderate/high) 
Outcomes and Analysis 
Handling of 
incomplete responses 
Internal validity May lead to biased assessment of test performance. 
Other analysis 
problems 
Internal validity Blinding of scorers of assessments, incomplete reporting of 
results, problems with statistical analysis, etc. 
Overall internal validity (good/fair/poor):  
Overall external validity 
(good/fair/poor): 
 
Comments: 
 
 
Data Synthesis and Analysis  
I conducted a qualitative synthesis of the primary and secondary outcomes, as available, 
for each included study. I did not conduct a formal assessment of heterogeneity. 
 
RESULTS 
 I identified and reviewed 475 unique titles and abstracts through the stated search 
strategy. I excluded 467 of these on the basis that they were not relevant (did not address 
clinician prediction of life expectancy), assessed predictions on the wrong patient population, or 
assessed predictions of life expectancy that averaged less than one year. I selected eight 
studies for review of full text, excluded two of these for irrelevance, and included six cross-
sectional studies in the final review (see Figure 1 below). All included studies addressed 
clinician performance at predicting life expectancy using questionnaires that involved patient 
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vignettes or simple demographics. There were no studies that involved physician prediction of 
life expectancy in real patients over the time period I specified; these type of studies appear to 
be limited to predictions over short time periods5 or narrow patient populations.38 
 
Figure 1. PRISMA flow diagram of included studies 
 
Summary Description of Included Studies 
Table 4 summarizes the methods and results of the six included studies, all of which use 
patient vignettes in their design. All studies were published in the last ten years and took place 
in Germany, the United Kingdom, Canada, or the United States. Half of the studies (n=3) 
addressed LE prediction in the context of prostate cancer treatment decisions, referencing 
guidelines that limit active treatment of prostate cancer to patients with adequate LE. The 
studies enrolled modest sample sizes (n = 18 to 211) of clinicians, including physicians and 
252 studies excluded on review of title & abstract 
--245 not involving physician predictions 
--4 wrong group for prediction (e.g., patients with   
      terminal illness) 
--3 wrong time period (e.g., < 1 yr) 
8 full-text articles assessed 
2 studies excluded on full text review because 
do not involve physician predictions 
6 studies included in qualitative review 
253 records by MEDLINE search 
193 records by EMBASE search 
84 records by PsycINFO search 
 260 total records after  
     duplicates removed 
3 records found by hand search of bibliographies  
4 records found by MEDLINE related articles searches  
   (208 records reviewed) 
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resident physicians from various specialties, medical students, nurses, and other staff such as 
physical and occupational therapists. For the purpose of this review, data were abstracted for 
physicians and resident physicians (except in the case of Walz et al. 2002, for which three 
medical students’ responses are mixed with 16 physicians’ responses). Physician only sample 
sizes ranged from n = 16 to 191. All studies provided subjects with paper surveys involving brief 
patient vignettes or scenarios. The reporting of responses is heterogeneous and includes 
subjects’ prediction of LE in years (3 studies); LE by range of years, e.g. <2, 2-5, 5-10, >10 
years (1 study); 10-year mortality risk as a percent (1 study), 10-year survival as yes or no for 
each subject (1 study); and 10-year survival of an entire cohort of patient vignettes as a percent 
(1 study). The subjects’ predictions are compared to various reference standards, which include 
LE derived from life tables without adjustment (1 study), LE from life tables divided into quartiles 
based on overall health status (1 study), LE from life tables with statistical adjustment for 
specific comorbidities (2 studies), LE prediction by a Markov model (1 study), and actual LE 
from retrospective study of a patient database (1 study). All studies provide some reporting of 
the subjects’ predictive accuracy and intra- or inter-rater reliability compared to these 
heterogeneous reference standards. 
Quality Summary of Included Studies 
 Quality assessment tables for each study are provided in Appendix B, and overall 
assessments of internal and external validity are summarized in the bottom rows of Table 4. 
Most studies received fair or fair-poor ratings in both areas. I did not consider any to have a 
definite fatal flaw warranting a poor rating. One study received a fair-good rating for internal 
validity based on thorough reporting of methods and a design specifically assessing 
prognostication in screening decisions. In general, internal validity was limited by the use of 
vignettes rather than real patients and the uncertain performance of reference standards used 
as proxy for real life expectancy. External validity was generally limited by the small sample 
  17 
  
sizes, convenience sampling of subjects or lack of reporting on subject recruitment, and paucity 
of primary care physicians among the included subjects.  
Summary of Primary and Other Outcomes 
 The reporting of outcomes is heterogeneous and not suitable for meta-analysis. I was 
able to abstract the results for physicians (including resident physicians) from those of other 
clinicians in all cases except the study by Walz and colleagues, in which case medical students 
are included but represented only 16% of the sample. In general, the studies show that 
physicians are moderately accurate at predicting the life expectancy of older adults, but have 
poor reliability as a group. Five out of six studies report that on average, physicians slightly 
underestimate LE, while one study reports variable estimation (Krahn et al.,35 reporting average 
overestimation for 5 vignettes and underestimation for 4 vignettes, average slight 
overestimation). For studies that reported LE predictions in years (n = 3), the prediction error (± 
standard deviation) ranged from -1.63 (± 3.70) years34 to +0.34 (± 3.29) years.35 Table 4 shows 
the results of the three studies that reported other outcomes.  
 Regarding physician attributes associated with their predictive performance, reporting is 
limited and heterogeneous. Two studies (Walz et al. 200739 and Clarke et al. 20093) report no 
differences in predictive performance between physicians and physicians-in-training, suggesting 
that years of training may not be associated with performance. One study (Wilson et al. 200540) 
reports better performance among senior consultants than among junior doctors; however, they 
do not report whether this difference is statistically significant and furthermore the senior 
physicians were of different specialties than their juniors (urologists and oncologists vs. 
surgeons), so it is not clear whether the trend may be due to years of experience or specialty. 
One study did find that specialty significantly influenced accuracy (Wirth & Sieber 2012,34 
geriatricians are more accurate than non-geriatricians), while another found that specialty is not 
associated with performance (Krahn et al. 2002,35 urologists vs. radiation oncologists). Wirth 
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and Sieber further reported that neither subjects’ age nor gender is associated with predictive 
performance. No studies examined any other demographic factors. 
 With regard to other trends in outcomes, three studies3, 34, 35 reported that accuracy in LE 
prediction decreased as LE determined by the reference standard increased. Two studies34, 35 
further reported that physicians’ reliability decreased as reference LE increased.
Study Clarke et al. 2009
3
 
Eur J Intern Med 
Krahn et al. 2002
35
 
Urology 
Lewis et al. 2008
41
 
Med Decis Making. 
Subjects 60 clinicians (20 physicians, 20 nurses, 
20 medical students) 
191 urologists and radiation oncologists 50 internal medicine resident physicians 
Setting United Kingdom Canada North Carolina 
LE prediction 
assessment tool 
57 unique patient vignettes + 13 
duplicate vignettes 
18 patient vignettes 3 patient vignettes repeated for 2 ages 
Characteristics 
of assessment 
--Include gender (M or F), age (mean 
68 y.o.), brief PMH of common medical 
conditions and severity 
--Actuarial LE 2 to 28 yrs 
--2 male patient vignettes, each with 3 
ages (55, 65, 75 y.o.) and 3 levels of 
comorbidity described in several phrases 
--Model-predicted LE 1.8 – 22.0 yrs 
--Include gender (female), age (75 or 85 
y.o.), and brief PMH 
--3 levels of health representing top, middle, 
or bottom quartiles for age 
--Actuarial LE 3-17 yrs 
Prediction 
outcome(s) 
Life expectancy Life expectancy and 10-yr survival (alive 
or dead) 
Life expectancy  
(categories: <2, 2-5, 5-10 or >10 yrs) 
Reference 
standard for LE  
Comorbidity-adjusted actuarial LE 
--Government Actuary Department’s 
2001-2004 interim life tables adjusted 
using Brackenridge’s Medical 
Selection of Life Risks 
Two-state Markov model created by 
group. --Two variables – age, 
standardized level of comorbidity (ICED). 
Age-adjusted LE from Statistics Canada 
life tables.  
--Adjustment for comorbidity entered as 
annual HR of dying for each ICED level.  
Life tables (age, gender)  
--National Center for Health Statistics – Life 
Tables of US 1997, divided into quartiles of 
LE for each age 
Subject accuracy 
 
Mean LE underestimated by 1.46 (0.31 
to 2.61) yrs (MDs only) 
--Avg RMSE: 4.99 (4.71 to 5.28) yrs 
(all subjects) 
Mean LE overestimated by 0.34 yrs 
--82% correctly predicted > or < 10 yr LE  
--Avg RMSE 2.4 – 5.2 yrs 
48% rate of underestimation (by 1-2 LE 
categories) vs. 2% rate of overestimation 
(by 1 LE category)  
Subject reliability 
 
Intra-rater reliability: 0.91 
Inter-rater reliability: 0.66  
(MDs only) 
Std dev of LE estimations range from  
1.8 to 4.6 years, decreasing with vignette 
age 
Moderate agreement to 2-3 age categories 
per vignette 
Tendency toward 
overestimation or 
underestimation? 
Underestimation Variable (overestimation in 5 vignettes, 
underestimation in 4 vignettes; average 
slight overestimation) 
Underestimation 
Other findings Similar performance between 
physicians, nurses, and med students -
-Accuracy generally ↓ as LE ↑ 
Error in predicted LE increased by 1.08 
years per 1 year of model-predicted LE 
Majority of subjects would not offer CRC 
screening to pts with LE < 2 yrs, would let pt 
decide for LE 2-10 yrs, and would 
recommend screening for LE > 10 yrs 
Clinical context Open-ended Prostate cancer management decision Colorectal cancer screening decision 
Internal validity  Fair Fair Fair - Good 
External validity  Fair - Poor Fair Fair 
Table 4. Characteristics of Included Studies (Methods and Results)  
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Study Walz et al. 2007
39
 
BJU Int. 
Wilson et al. 2005
40
 
BJU Int. 
Wirth and Sieber 2012
34
 
Gerontology 
Subjects 19 clinicians (6 urologists, 10 resident 
physicians, 3 medical students) 
18 physicians (8 urologists, 2 oncologists, 
8 surgeons) 
211 lecture attendees (51 physicians, 38 
medical students, 122 others including 
nurses, OTs, PTs, NAs) 
Setting Canada - Quebec United Kingdom Germany 
LE prediction 
assessment tool 
50 patient vignettes Same as Clarke et al. 2009 8 hypothetical patient groups 
Characteristics 
of assessment 
--Include gender (male), age (median 
67 y.o.), comorbidity list, CCI score 
(median 2) 
--Actual survival: 60% at 10 yrs 
Same as Clarke et al. 2009 --Men and women ages 0, 70, 80, and 90 
--Actuarial LE 3.9 to 82.5 yrs 
Prediction 
outcome(s) 
10-yr survival (alive or dead) 10-yr mortality risk Life expectancy 
Reference 
standard for LE 
Actual patient mortality 
--Quebec Health Plan database 
reporting of vital status for 50 randomly 
selected patients 
--Actuarial data also used to predict LE 
as a second reference standard; 
methods not reported 
Comorbidity-adjusted actuarial LE  
--Life tables adjusted using Brackenridge’s 
Medical Selection of Life Risks plus 
Charlson Index to derive 10-yr mortality 
risk 
Actuarial LE from life tables (age, gender) 
--Statistisches Bundesamt: German death 
statistics 2007-2009 
 
Subject accuracy Mean subject-predicted 10-yr survival of 
vignette cohort underestimates actual 10-
yr survival by 14.0% (46.0% predicted vs. 
60.0% actual) 
--C-statistic for predicting 10-yr survival: 
0.68 (0.64-0.71) 
Mean mortality risk underestimated by 
10.8% (95% CI 10.1-11.5%) 
MDs only: 
--Mean LE underestimated by 1.63 years 
(2.44 yrs for 70 y.o. adults, 1.81 years for 
80 y.o. adults, 0.64 years for 90 y.o. adults) 
Subject reliability Range of predicted survival: 20.0% of 
vignette cohort to 70.0% of vignette 
cohort 
Intra-rater reliability: 0.74 (0.31 - 0.94) 
Inter-rater reliability: 0.56 – 0.58 
Std dev of LE estimations range from  
1.6 to 4.3 years, decreasing with vignette 
age 
Tendency toward 
overestimation or 
underestimation? 
Underestimation Underestimation Underestimation 
Other findings Similar performance between 
urologists, residents, and medical 
students 
Surgeons were least accurate (were also 
the most junior subjects) 
Participants with geriatrics training less 
likely to underestimate LE 
--Accuracy generally ↓ as LE ↑ 
Clinical context Prostate cancer management decision Prostate cancer management decision Open-ended 
Internal validity Fair - Poor Fair Fair - Poor 
External validity  Fair - Poor Fair - Poor Fair 
Table 4 (con’t). Characteristics of Included Studies (Methods and Results)
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A brief summary of the methods, results, and quality of the six included studies are listed 
below, in order of decreasing validity and relevance to the key question. Please see Appendix B 
for more detailed reporting. 
Lewis et al. 200841 
 Lewis and colleagues recruit a convenience sample of internal medicine resident 
physicians (n = 50) in North Carolina with the aim of assessing both their LE prediction 
performance and associated colon cancer screening recommendations. The resident physicians 
are provided 6 patient vignettes including age (75 y.o. or 85 y.o.), gender (all female), and brief 
comorbidity with severity (3 levels) intended to represent women in the bottom  quartile, middle 
two quartiles, or top quartile of health for her age. They are asked to predict the patient’s LE in 
years (open-ended), their recommendation regarding colorectal cancer screening (recommend 
against, recommend for, let the patient decide, or do not discuss), and whether or not they are 
uncertain about their recommendation (yes/no). The reference standard is based on the Walter 
& Covinsky 20011 framework for screening older patients, and uses LE derived from life tables 
which is then divided into quartiles (25th, 50th, or 75th percentile).  
 The resident physicians’ responses for LE are reported according to the following 
categories: < 2 years, 2-5 years, 5-10 years, or > 10 years. The residents choose the correct 
(actuarially determined) LE category 51% of the time, underestimate by 1 or 2 categories 48% 
of the time, and overestimate by no more than 1 category 2% of the time. For each patient 
vignette, the spread of responses is over 2-3 age categories. The residents’ screening 
recommendations varied with their predicted LE; those who predicted > 10 years LE would 
either recommend screening or let the patient decide and most who predicted < 2 years would 
recommend against or not offer screening. For predicted LE of 2 – 10 years, there was a broad 
range of screening recommendations with 61% choosing to let the patient decide. A high 
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proportion of residents reported uncertainty about their screening recommendations (48-86%, 
depending on vignette). 
 This study earns a “fair–good” rating for internal validity. Strengths include thorough 
reporting of methods including survey design and distribution and a high response rate of 96%. 
One weakness is that the precision of the reference standard may be limited due to the 
approximation of health status into quartiles. The study earns a “fair” rating for external validity 
due to its inclusion of residents only (more experienced physicians may perform differently) and 
relatively few vignettes. The vignettes are reasonably sophisticated in their design and 
encourage residents to think about LE in terms of screening decisions.  
Krahn et al. 200235 
 The purpose of this Canadian study is to determine urologists and radiation oncologists’ 
performance at predicting the LE and 10-year survival (alive or dead) for typical prostate cancer 
patients, in order to identify candidates for curative therapy (LE > 10 years). The authors mail 
surveys to all actively-practicing adult urologists and genitourinary radiation oncologists 
registered with appropriate professional organizations, and achieve a 69% response rate (n = 
138 urologists, 53 radiation oncologists). The subjects are provided 18 patient vignettes of men 
with localized prostate cancer, but are instructed to determine the patients’ years to death from 
other causes besides the cancer. They are also asked to select one of three prostate cancer 
management options for the patients. The vignettes include age (55, 65, or 75 y.o.), gender (all 
male), and comorbidity (3 levels: healthy, moderate, or severe comorbidity). The reference 
standard for LE is derived from a 2-state Markov model developed by the authors that 
incorporates data from life tables and the Index of Coexistent Disease (ICED). The model 
predicts a range in LE of 1.8 – 22 years for the patient vignettes. 
 On average, the physicians underestimate LE by 0.34 years, with a standard deviation 
ranging from 1.8 to 4.6 years for each vignette (data received from direct correspondence with 
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study authors and reported in Appendix B). Overall, 31% of physicians’ predictions were 
accurate within +/- 1 year of model-predicted LE, 48% were within 2 years, and 67% were within 
3 years. The RMSE for the physicians’ estimates ranged from 2.4 to 5.2 years, depending on 
the vignette. When asked to predict 10-year survival (yes/no), physicians were correct 82% of 
the time. Clinicians’ error increases by 1.08 years per year of the model’s prediction. Neither 
patient age nor comorbidity are associated with physician error, however. 
 The study earns a “fair” rating for internal validity; main limitations are the unsupervised 
completion of surveys by study participants (opportunity for “cheating”) and unclear validity of 
the model created by the study authors to predict LE as a reference standard. The study also 
earns a “fair” rating for external validity; strengths include their sampling design for subject 
selection and use of patient vignettes that would be appropriate for difficult screening decisions, 
while weaknesses include the lack of primary care doctors in their sample and lack of female 
patient vignettes. 
Clarke et al. 20093 
The authors recruit 20 physicians and 40 medical students and nurses in the United 
Kingdom by an unclear recruitment strategy and provide them with 57 unique and 13 duplicate 
patient vignettes. Two physicians are general practitioners. The vignettes included patient age 
(range 55 – 82), gender (both male and female), and a short description of comorbidities and 
their severity. The subjects are asked to predict LE for each vignette patient without reference to 
any particular clinical decision. The reference standard for LE is life tables for the United 
Kingdom adjusted down for comorbidity and severity using actuarial statistics, for a mean 
reference LE of 11.6 (range 2 to 28) years.   
Physician subjects underestimate the reference LE by a mean and 95% confidence 
interval of 1.46 (0.31 to 2.61) years. Forty percent of physicians have a statistically significant 
Spearman’s correlation between their prediction error and the average of their predicted and the 
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reference LE (error increased as reference LE increased). Physicians underestimate LE in 62% 
of cases and overestimated in 29%. Intra-observer reliability for physicians, based on the 13 
duplicate patient vignettes, was 0.91 (statistical derivation of this statistic not reported), while 
inter-observer reliability was 0.66. There are no statistically significant differences in the mean 
prediction errors of physicians, students, and nurses. 
This study earns a “fair” rating for internal validity based primarily on its moderately 
detailed patient vignettes and unclear accuracy of the reference standard as a proxy for actual 
LE. It earns a “fair—poor” rating for external validity based on the small sample of physicians 
including only two who would be expected to make cancer screening decisions in their work, 
lack of reporting about subject recruitment. On the other hand, the study’s patient vignettes do 
appear to represent the types of older adult outpatients who would face difficult screening 
decisions. 
Wilson et al. 200540 
Similar to both Krahn et al. and Walz et al., the study authors are interested in 
physicians’ predictions of the life expectancy of prostate cancer patients around the 10 year 
mark for making treatment decisions. The recruitment of 18 United Kingdom physicians (8 
urologists, 8 surgeons, and 2 oncologists) is not described. The physicians are given the same 
57 unique patient vignettes and 13 duplicate vignettes as described in the 2009 study by Clarke 
and colleagues,3 which include patient age (range 55 – 82), gender (both male and female), and 
a short description of comorbidities and their severity. Unlike the Clarke study, the physicians 
are asked to estimate mortality risk at 10 years as a percent for each patient. The reference 
standard is the same comorbidity-attuned LE from actuarial data as described in the Clarke 
study, but the authors further apply the Charlson Index to convert LE in years to mortality risk at 
10 years. 
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On average, the physicians underestimate mortality risk by 10.8% (range 3.9 to 33.2%) 
in absolute percentage points. Fifteen physicians predominantly underestimated, while three 
predominantly overestimated. Intra-rater reliability is reported as 0.74 (range 0.31 – 0.94) based 
on the 13 duplicate cases, while inter-rater reliability is 0.58 (derivation of this statistic is not 
reported). The authors note that if a 50% probability of survival to 10 years were used as a 
threshold for some medical decision for this subject group, as many as 34% of vignette patients 
would be denied treatment based on underestimation of LE, and 24% would be inappropriately 
offered treatment based on overestimation of LE. 
This study earns a “fair” rating for internal validity; concerns include unclear accuracy of 
their reference standard and a potential intellectual conflict of interest in that the authors are 
engaged in the development of a software tool to help physicians predict LE, which may have 
led them to interpret subjects’ performance in a poorer light. The study earns a “fair—poor” 
rating for external validity based on the small sample size, lack of reporting about subject 
selection and subject demographics, and exclusion of primary care physicians.  
Wirth and Sieber 201234 
 This German study is unique in that it subjects are asked to predict the LE of patient 
scenarios based on age and gender alone, without information about health status. The authors 
recruit 211 health care workers (51 physicians including 11 geriatricians and 160 others) who 
are attendees of the primary author’s lectures on general medicine topics. The subjects are 
asked to predict the LE in years of average German men and women age 0, 70, 80, and 90. 
They are not offered any particular clinical context. The reference standard is LE derived from 
life tables. 
 I obtained data for the 51 physicians from the primary author and excluded data for 
infants (age 0). On average, physicians underestimated LE by 1.63 years with a standard 
deviation of 3.70 years. Both their accuracy and reliability increased as actuarial LE decreased. 
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For example, their average (± standard deviation) prediction error for the 70 y.o. woman with an 
actuarial LE of 16.4 years was -2.02 (±4.34) years, but for the 90 y.o. man with an actuarial LE 
of 3.9 years it was -0.03 (± 2.05) years. Compared non-geriatricians, geriatricians’ (n = 11) 
predictions were more accurate and had similar reliability: average LE underestimated by 0.69 
(± 3.37) years. 
 This study earned a “fair—poor” rating for internal validity; the main limitation is that 
physicians were asked to determine LE for average patients of an age and gender without 
knowledge of any health information. It is likely that in real life, information about patients’ health 
or other factors would alter these age/gender LE predictions to a greater or lesser extent. On 
the other hand, the reference standard may be considered more accurate to real life because 
the life table estimates were not adjusted for comorbidity in a way that may introduce 
uncertainty. The study earned a “fair” rating for external validity for its relatively modest sample 
size and selection of lecture attendees who may differ in some way from primary care 
physicians at large. 
Walz et al. 200739 
 Similar to Krahn and colleagues, the purpose of this Canadian study is to determine 
clinicians’ performance at predicting 10-year survival (alive or dead) for typical prostate cancer 
patients, in order to identify candidates for curative therapy vs. watchful waiting. The recruitment 
of 6 urologists, 10 resident physicians, and 3 medical students in Quebec province is not 
described. These 19 clinicians are provided 50 patient vignettes that are based on real patient 
data obtained through retrospective review of a health insurance database, including age 
(median 67 y.o.), gender (all male), and comorbidities as reported by ICD-9 codes. All patients 
also had prostate cancer, but subjects were instructed to ignore this diagnosis and determine 
10-year survival (yes/no) for each patient based on other causes. The reference standard was 
each patient’s actual vital status at 10 years. This study is unique in that it is the only study that 
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uses real patient data. The authors additionally determined actuarial LE (converted to 10-year 
survival) for each patient, but do not report how this actuarial LE was derived.  
 On average, the clinicians predicted that 46.0% of the cohort of 50 vignette patients 
would survive to 10 years, with a range for 20.0% to 70.0%. The actual 10-year survival of the 
cohort is 60.0%, while the actuarial-predicted survival is 57.3%. Therefore, the clinicians on 
average underestimated the cohort’s actual survival by 14 percentage points (absolute 
difference). Results for physicians (n = 16) cannot be separated from medical students (n = 3) 
from the data provided. Results for individual patients within the cohort of 50 vignette patients 
are also not omitted. Receiver operating curves for the three types of clinicians are provided. 
The area under the curve (AUC) of the ROC for urologists is 0.67 with a 95% CI of 0.60 – 0.72; 
similarly for resident physicians it is 0.69 with a 95% CI of 0.64 – 0.74. 
 This study earns a “fair–poor” rating for internal validity. Major concerns include the use 
of ICD-9 codes to describe the vignette patients’ comorbidities; the coding of actual patients’ 
conditions may be incomplete and may not describe the severity of a condition. For instance, 
there is only one ICD-9 code for Alzheimer’s type dementia, which could indicate mild cognitive 
impairment with a relatively benign course or advanced, immobilizing dementia with a very poor 
prognosis. Furthermore, there is no description of how the vignettes were administered. The 
study also earns a “fair-poor” rating for external validity because of its small sample size, 
omitted reporting of the subject selection process and of subject demographics, and exclusion 
of primary care providers who might make cancer screening decisions (the specialties of 
resident physicians are not reported). 
Physician Reliability Declines with Increasing LE  
To determine whether the reliability with which physicians predict patients’ life 
expectancies varies with patients’ actuarial life expectancies, I examined the standard deviation 
of physician predictions as a simple measure of the breadth of the distribution of individual 
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physician predictions for a given patient. The two authors I contacted for original data (Krahn et 
al. 2002 and Wirth and Sieber 2012) provided this information. Krahn and colleagues report the 
standard deviation of 191 physicians’ predictions for 18 patient vignettes with unique model-
predicted LE. Wirth and Sieber report the standard deviation of 51 physicians’ predictions for 6 
patient scenarios with unique actuarial LE. I report results for the larger study, Krahn et al., 
below. I examined Wirth & Sieber separately and found a very similar trend. 
  
Figure 2. Reliability of physicians’ predictions declines with increasing model-predicted life 
expectancy, Krahn et al. 2002.35 Simple linear regression applied. 
 
Figure 2 plots the standard deviations against model-predicted (reference) LE. In general, as 
actuarial LE increases, physicians’ predictions become increasingly unreliable or imprecise 
(standard deviation increases). I used linear regression to generate a very rough estimation of 
the standard deviation that would be expected for patients with model-predicted life 
expectancies of 5, 10, 15, and 20 years. Table 5 reports these rough estimates, which are 
similar to those derived from the Wirth & Sieber data. 
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Model-Predicted LE Standard Deviation of 
Predicted LE (yrs) 
5 years LE 2.8 
10 years LE 3.3 
15 years LE 3.7 
20 years LE 4.1 
Table 5. Reliability of physician-predicted LE depends on patient’s actual LE.  
 
For patients who have an expected 5 years of life remaining, the expected standard deviation is 
close to 3; in other words, out of a sample of physicians like those in Krahn’s study, roughly two 
thirds would be expected to predict a LE between 2 and 8 years. For a patient with an expected 
20 years of life remaining, about two thirds would be expected to pick between 16 and 24 years. 
 
DISCUSSION 
 
 This systematic review attempts to characterize the accuracy and reliability of health 
care providers’ predictions of life expectancy for older adult outpatients, as well as attributes 
associated with predictive performance. The quality of 6 identified studies is limited and their 
reporting of results heterogeneous. Overall, physicians are moderately accurate in their 
predictive ability for the life expectancy of patient vignettes. As a group, they have a tendency to 
underestimate life expectancy by 1–2 years and 10-year mortality risk by 10-15%. As individuals, 
however, predictive performance varies greatly with poor reliability among individuals. This poor 
reliability has important implications for the use of life expectancy in screening decisions.  
Implications for Screening Decisions 
 Three questions are important when it comes to the use of provider predictions of life 
expectancy when making cancer screening recommendations. First, are providers willing to 
undertake a complex individualized approach to screening decisions, considering numerous 
individual patient factors, as opposed to a simpler, age based rule? Second, are primary care 
providers as a whole able to accurately and precisely predict older patients’ life expectancy 
above or below a particular threshold? Third, if yes to the first and second questions, to what 
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degree will providers use information about life expectancy when making final screening 
decisions with their patients? This third question is relevant because many factors may enter 
into screening decisions, including patient preferences, physicians’ responses to different and 
competing guidelines, peer influences, financial incentives and rules set up by practices, and so 
on. 
 This systematic review attempts to answer the second question only. In the case of 
cancer screening, we are interested in predicting life expectancy above or below a threshold at 
which the probability of a patient benefiting from cancer screening outweighs the probability of 
her being harmed by the screening. This threshold has also been referred to as a “lag time”1113 
to benefit, referring to the idea that cancers for which we have screening tests require some 
years to grow from a screen-detectable but asymptomatic tumor to a potentially fatal tumor 
burden. In randomized controlled trials of cancer screening, survival curves for screened and 
unscreened groups are not observed to separate until five (breast cancer)42 or approximately 
four to five (colorectal cancer)43 years. However, it is important to remember that patients must 
not only live long enough to potentially benefit from screening, but also long enough that the 
magnitude and likelihood of potential benefit outweighs the magnitude and likelihood of potential 
harms. Therefore, it may be the case that this benefit-to-harm ratio is not favorable until 10, 15, 
or even 20 years depending on how one chooses to weigh benefits against harms. Furthermore, 
there are few randomized controlled trials of cancer screening including patients over age 70, so 
the changes in harms of screening that may be experienced with increased age and comorbidity 
can only be estimated.13 The issue of threshold choice is discussed further below. 
 Returning to the second question, then, are primary care providers accurate and precise 
enough to predict life expectancies above or below a threshold of 5, 10, 15, or 20 years? In 
short, the data are varied but physicians are moderately accurate at predictions around the 5 
and 10 year thresholds, and their poor reliability as a group becomes a limiting factor at 
predictions over longer time periods. Three studies directly address thresholds. The physicians 
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queried by Krahn et al. correctly predicted patients’ life expectancy above or below a 10-year 
threshold 82% of the time.35 The resident physicians studied by Lewis et al. were correct above 
or below a 10-year threshold 75% of the time (excluding one patient vignette with a LE of 
exactly 10 years) and above or below a 5-year threshold 77% of the time.41 Wilson et al. asked 
physicians to predict 10-year mortality risk. If a ≤50% mortality risk were used as the threshold 
for screening, then physicians would correctly predict over or under only 42% of the time. If the 
threshold were changed to only screen patients with a ≤30% mortality risk, however, then 
physicians would improve to correctly predicting over or under 69% of the time.40 
The decreasing reliability of physicians’ life expectancy estimates made over longer 
periods of time is important because it indicates that, for higher life expectancy thresholds, 
physicians become less reliable as individuals. The importance of this decreasing reliability 
depends on the life expectancy threshold one chooses for screening decisions. Table 5 
presents very rough estimates of physicians’ reliability at life expectancy thresholds of 5, 10, 15, 
or 20 years based on one modest-sized study. Unfortunately, it is difficult to determine 
physicians’ average accuracy around these thresholds because complete data sets allowing 
interpolation are only available for the Krahn et al. and Wirth & Sieber studies, which have 
different trends regarding accuracy (Krahn et al. is the only study that does not show consistent 
underestimation of life expectancy). 
It is important to remember that in clinical practice, physicians do not always make a firm 
recommendation for or against cancer screening, but may share information with the patient and 
encourage him to make a screening decision through informed decision making. In their study of 
resident physicians, Lewis et al. asked participants to make a screening recommendation, 
including the option to “let the patient decide.” Letting the patient decide was positively 
associated with reported clinical uncertainty, and the majority of all recommendations (53%) 
were to let the patient decide.41 This finding by Lewis and colleagues may reflect the relative 
inexperience of residents as physicians-in-training, but it may also reflect moderately high rates 
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of informed or uninformed decision making in clinical practice. Patients’ choices may be a 
moderate driver of the screening rate of older adults.41 
Physician predictions versus prediction rules for life expectancy 
 While this review has examined physicians’ predictions of life expectancy based on 
experience or intuition, there are, of course, resources available to physicians to assist them in 
their predictions. Life tables for large populations are readily available online. In their much-
referenced framework for individualized cancer screening decisions,1 Walter and Covinsky 
further provide life expectancies for older U.S. men and women broken down by quartiles of 
health. Finally, a number of moderately sophisticated prediction rules for life expectancy have 
been developed and validated in prospective cohorts of older adults. A 2012 systematic review 
by Yourman and colleagues summarizes the characteristics and quality of these prognostic 
indices.2 Of note, only two of these indices extend over a period of years that might be 
appropriate for cancer screening. The first index developed by Lee and colleagues predicts 4-
year mortality risk for community-dwelling older adults.44 The second developed by Schonberg 
and colleagues predicts 5-year mortality risk for community-dwelling adults over age 65,45 with 
extended follow-up to 9-year mortality.46 Both require similar inputs of 11-12 risk factors for 
mortality including biometric factors, comorbidities, and functional status, and produce scores 
that correspond to mortality risk ranging from <5% to 64% (Lee et al.) or 7% to 92% (Schonberg 
et al. 9 year mortality risk). Both are available in an interactive format online.4 Depending on the 
life expectancy threshold agreed upon for cancer screening, these indices might or might not 
extend far enough to assist screening decisions. Yourman et al. describe these indices as being 
well calibrated with good to very good discrimination, but overall conclude that prospective 
testing of the indices in samples larger and more diverse than their validation cohorts is lacking, 
and there is insufficient evidence to recommend the widespread use of either.  
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 An important question remains as to whether physicians’ predictions or predictions 
based on a “tool” such as one of these prognostic indices or the Walter and Covinsky framework 
do a better job of estimating patients’ true years of life remaining. Unfortunately, I have been 
unable to find a satisfactory head-to-head comparison for life expectancy predictions made over 
many years. The studies of physicians’ predictions in this review cannot be indirectly compared 
to prognostic indices because there is not enough patient information contained in any of the 
patient vignettes to calculate a score using a prognostic index. 
In his review article on prognostication, Kellet briefly discusses literature comparing 
physicians’ intuition to prediction models in other, generally short-term clinical scenarios, such 
as post-surgical outcomes and survival among patients in intensive care units.47 In some cases 
clinicians perform as well as or better than available prediction tools, and in other cases they fall 
short of the predictive tools’ accuracy. For example, several studies have compared scores from 
the APACHE II scoring system for intensive care patient mortality to physicians’ predictions of 
mortality, and found that physicians predictions’ and APACHE scores were similar in their ability 
to predict real patient outcomes.48-50 This type of prognostication over the short term based 
largely on physiologic data differs from predictions of life expectancy over many years in the 
context of cancer screening, however. Further research is needed to compare humans to 
prediction rules in this context. 
It is possible that physicians’ use of prediction tools along with their own clinical 
judgment may be superior to the use of either alone. As part of their study of resident physicians’ 
screening decisions for patient vignettes, Lewis and colleagues41 asked participants to predict 
the life expectancy of three 85 y.o. women independently, then provided them with life tables 
including quartiles. Access to this tool was associated with 26% of residents changing their 
screening recommendation for one of the three vignettes, but no significant change in 
recommendations for the other vignettes. At least in this one very particular scenario, physicians 
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are not greatly influenced by their access to this tool, but a modest proportion found it of great 
enough value to change their recommendations. 
Limitations of this Review 
 Limitations of this systematic review include the absence of a second reader, as well as 
the decision to include studies that may be deemed by some readers to have low quality due to 
one of the several limitations of the evidence listed below. I chose to report on all studies that 
met eligibility criteria in this report in order to include as much evidence as possible for this 
understudied research question, regardless of quality. I am encouraged that, despite the 
limitations of individual study designs, the authors generally draw similar conclusions from their 
results. Finally, a second reader would have been valuable for a review such as this one to 
verify appropriate inclusion and exclusion of studies, as well as abstraction and reporting of 
results. 
Limitations of the Evidence 
Patient Vignettes as a Proxy for Real Patient Encounters 
 A common limitation to all of the included studies in this review is their reliance on paper 
surveys with patient vignettes as a substitute for live patient encounters. For each study, the 
information contained in these vignettes is limited to a few lines or less (in the case of the Wirth 
& Sieber study, just the patient’s age and gender). In real life outpatient scenarios, physicians 
would likely have access to much more information, such as details of the past medical history, 
information about the patient’s functional status, smoking status, self-perceived health, and 
other factors that have been associated with life expectancy in cohort studies.4445 The 
appearance and behavior of a live patient may helpfully inform or unhelpfully bias the 
physician’s life expectancy assessment. Physicians are also susceptible to cognitive biases that 
may alter their assessments of live patients in ways that are not measurable with patient 
vignettes. Studies51 have shown, for example, that physicians are more likely to believe that 
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their patients will experience a particular bad outcome if they have recent experience with that 
bad outcome in other patients, due to the so-called availability heuristic. Physicians may also 
have a tendency to over or under prognosticate based on their positive or negative feelings 
toward a patient due to visceral bias.52 It is unclear how prevalent and significant these and 
other cognitive biases are, but they may exist in live patient interactions in ways that they do not 
in interactions with patient vignettes. 
On the other hand, some literature suggests that physicians’ responses to patient 
vignettes may in fact model their behavior in live patient scenarios. In one study,53 
rheumatologists were asked to record brief notes on the signs and symptoms of rheumatoid 
arthritis patients they had just seen in clinic, as well as an assessment of their level of disease 
activity. Several weeks later, the same rheumatologists were presented with hypothetical patient 
vignettes containing the same signs and symptoms they had previously recorded. The study 
found that the physicians formed the same assessment of disease activity for the “paper 
patients” as they had following the live encounters with a correlation coefficient of 0.901. In the 
majority (65%) of cases, rheumatologists only recorded and, later, had access to 5 key signs 
and symptoms. These findings suggest that physicians may indeed make the same decisions 
about patient vignettes as they would for live patients, even when limited clinical information is 
available. On the other hand, the physicians in this study had the ability to record whatever 
information they considered most important, whereas in the studies on life expectancy, 
physicians could not choose the information they considered most important but only react to 
information provided. 
In another study,54 the quality of internal medicine physicians’ care decisions for vignette 
patients with heart disease was compared to their care decisions during interactions with 
standardized patients with identical characteristics to the vignettes. Investigators found that the 
overall quality score physicians earned for their decisions for vignette patients was similar to 
their score for standardized patients (71.0% vs. 76.2%). This finding suggests that physicians 
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may make similar assessments of and decisions for patient vignettes and live patients. Unlike 
the brief patient vignettes in the life expectancy studies, however, the vignettes in this study 
were lengthy and included information corresponding to a full patient history and physical.  
Based on these studies alone, it is difficult to determine whether or to what extent the patient 
vignette format affects the findings of the included studies. 
Heterogeneity and Unclear Accuracy of Reference Standards 
 
 Another potential limitation common to all the included study is their use of actuarial data 
with or without comorbidity adjustments as a yardstick against which to judge the physicians’ 
predictions. Each study chose or developed a different reference standard for life expectancy, 
hindering comparison of the studies to each other. It is difficult to determine which reference 
standard is most appropriate or accurate to real life. One study (Walz et al. 2007) did examine 
real patient data including years until death, and compared actuarial life expectancy (adjusted 
for comorbidity) at the time of the patient’s evaluation to their actual years until death. These 
authors only present data at the “cohort level” for their 50 patients, but find that the actuarially 
predicted 10-year survival of the cohort (57.3%) resembles the cohort’s actual survival (60.0%). 
A different study author went on to praise the actuarial data used by life insurance companies 
and in his study as “evidence-based and continually updated…[representing a] validated and 
reliable data source with greater applicability compared with individual hospital patient 
outcomes.”3 The methods behind these actuarial data and their performance in different patient 
groups are not readily available to me, however.  
Selection of Subjects 
 A third limitation common to all studies is the modest sample sizes (n = 18-191) and 
non-random sampling of subjects. The smallest sample sizes are surprising. Compared to the 
effort obviously extended by the authors in designing and analyzing the questionnaires, it would 
seem that recruiting a moderate, convenience sample of subjects would be an easier task. 
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Although some studies describe themselves as pilot studies, none have published follow-up. 
The small samples of volunteer subjects largely limit the generalizability of the studies’ findings. 
Clinical Context of LE Predictions 
 A fourth limitation to the evidence as a whole is the heterogeneity of clinical contexts in 
which the life expectancy question is asked. Three studies asked subjects to predict LE in the 
context of deciding whether or not to actively treat prostate cancer, two studies were open 
ended about the potential use of subjects’ life expectancy predictions, and only one study 
(Lewis et al.) specifically asked for predictions in the context of cancer screening decisions. It is 
possible that physicians’ performance, which may be influenced by personal biases, varies 
depending on the clinical context. 
Considering these limitations, an ideal study to address the key question would be a 
prospective cohort study in which primary care providers make life expectancy predictions for 
their own older patients based on information that is readily available in the outpatient setting. 
The patients are then followed over many years, ideally two decades, to track vital status. While 
this study would require a great time investment, it could potentially be added in concert to a 
separate study that tracks mortality in a cohort of older adults. Similar studies have collected 
data on community-dwelling adults through national surveys (e.g., the National Health Interview 
Survey) and then followed these subjects for up to 9 years46 to track mortality, but none of these 
studies have examined provider-predicted life expectancy. 
FURTHER DISCUSSION: HOW SHOULD WE EVALUATE A NEW CANCER SCREENING 
RULE? 
 
Revisiting guidelines for stopping cancer screening 
 Guidelines for deciding when to stop cancer screening in older adults are evolving, 
reflecting clinical uncertainty around this complex issue. Consider breast cancer screening. 
Through the late 1990s until 2002, guidelines for breast cancer screening were age-based, with 
various conflicting age thresholds. The US Preventive Services Task Force recommended 
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stopping at age 70, the American College of Physicians at age 75, the American Geriatric 
Society at age 85, and the American Cancer Society said nothing about stopping screening.17 A 
limitation of these age-based guidelines, however, is that they are unable to account for the 
heterogeneity in health status and disability observed among older adults of the same age, 
which increases to an extent as individuals age.1 This heterogeneity leads to a broad 
distribution of life expectancies; for instance, 80 y.o. US women at the 25th percentile of health 
are expected to live 4.6 years, while those at the 75th percentile are expected to live 13 years 
(1997 data).1 The breadth of this distribution matters because the potential benefits of cancer 
screening decline with decreasing life expectancy, while the likelihood of certain harms may 
increase with declining health status. 
In the 2000s, guideline development groups began to incorporate life expectancy, to a 
greater or lesser extent, into their recommendations for cancer screening (see Table 1). There 
is currently little consensus about how to estimate life expectancy or what life expectancy 
threshold should guide screening for different cancers. While age itself is a predictor of life 
expectancy that becomes increasingly important as individuals age, numerous other clinical and 
demographic factors contribute to life expectancy. 
Should age-based guidelines for cancer screening be replaced by a new screening 
guideline that incorporates estimates of life expectancy based on additional factors? What 
should the criteria be for evaluating this proposed new screening rule and comparing it to an 
age-based guideline? If a life expectancy-based screening rule is appropriate, how should we 
decide the life expectancy threshold for screening? These questions are critical to addressing 
the problem of overscreening and underscreening our aging population. 
Proposed criteria for evaluating a new screening rule for older adults 
Table 6 lists my proposed criteria for evaluating a new screening guideline for older 
adults that is based, among other potential factors, on an individualized assessment of patients’ 
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prognoses. These criteria loosely follow the phases of evaluation of a novel risk marker 
proposed by Hlatky et al. of the American Heart Association in their interesting paper on risk 
markers for cardiovascular disease.55 In the discussion below, “new rule” refers to this new 
prognosis-based guideline. Prognosis may be measured in terms of life expectancy in years, 
mortality risk at a certain number of years expressed as a percentage, or by some health status 
score that is implicitly associated with life expectancy (e.g., Charlson comorbidity index56 or one 
of its modifications). “Prognostic method” refers to one or more of the methodologies for 
estimating prognosis; for example, simple physician prediction as evaluated in this systematic 
review, actuarial life expectancy with or without quartiles as proposed by Walter & Covinsky,1 or 
mortality risk from a prognostic index derived from a cohort as reviewed by Yourman et al.2 The 
new rule may be compared against current practice for stopping cancer screening, which is 
heterogeneous, or against an age-based rule for stratifying patients into screening-
recommended or screening-not-recommended groups, which is termed the “old rule” below. 
Criterion Requirements 
(1) Basic characteristics of 
new rule 
Establishes a fixed or flexible life expectancy or mortality risk 
threshold for a specific type of cancer screening. Endorses a 
method(s) of predicting that life expectancy that: 
 Is applicable to a large, diverse population of older adults 
 Makes predictions at least as far out (in years) as the life 
expectancy threshold 
 Involves a specific list(s) of prognostic factors that are 
generally available in the outpatient setting to guide 
predictions; these factors are shown to be independently 
associated with patient mortality 
(2) Performance of 
prognostic method(s) 
endorsed by new rule 
Through appropriate studies, the method(s) demonstrate(s) 
sufficient:  
 Discrimination: degree to which individuals with poor 
prognosis are distinguished from those with good prognosis 
(c statistic, etc.) 
 Calibration: closeness of predicted prognosis to observed 
prognosis in a cohort (calibration slope and intercept, etc.) 
In the case that multiple prognostic methods are endorsed by the 
new rule, these methods demonstrate sufficient inter- and intra-
observer reliability. 
 Different prognostic methods provide similar estimates for the 
same individual 
  40 
  
(3) Generalizability of 
prognostic method(s) 
endorsed by new rule 
Through appropriate studies, the prognostic method(s) 
demonstrate(s) sufficient: 
 Reproducibility2: performance in individuals who were not 
included in the development cohort, but from the same 
underlying population  
and/or: 
 Transportability2: performance in a different population from 
the development cohort or based on data collected by 
different methods than those used on the development cohort  
(4) Reclassification 
(incremental improvement 
of new rule over old rule or 
current practice) 
New rule reclassifies substantial groups of individuals into 
screening-recommended or screening-not-recommended groups 
as compared to the old rule or current practice (NRI index, etc.) 
 Amount of reclassification is substantial enough, when 
compared with feasibility (criterion #6) to justify changing 
screening rules 
(5) Improvement in clinical 
outcomes 
A randomized controlled trial of the new rule compared to the old 
rule or current practice demonstrates improvement in clinical 
outcomes  
 Outcomes may include decreased cancer-specific mortality 
(increased benefit) and/or decreased procedures and 
treatments (decreased harms) 
 Modeling studies may be helpful as prerequisites to a 
population trial 
(6) Feasibility and 
cost-effectiveness 
 
New rule demonstrates sufficient improvement in outcomes to 
justify logistical challenges to its implementation, including 
burden on physicians 
 A cost-effectiveness analysis demonstrates a reasonable 
cost per life-year gained by appropriately applying the new 
rule, based on change in overall screening rates 
Table 6. Proposed criteria for evaluating a new screening rule based on life expectancy. 
 
 
First, the new rule must satisfy some basic characteristics. It must establish a fixed or 
flexible threshold for life expectancy or mortality risk, above which a particular cancer screening 
is recommended, and below which it is not recommended (either, no recommendation is made 
for or against screening, or there is a recommendation against screening). Another option is for 
a new rule to establish two life expectancy thresholds with the following breakdown: above the 
upper threshold screening is recommended, between the two thresholds there is no screening 
recommendation (decision is deferred to the patient), and below the lower threshold there is a 
recommendation against screening. The choice of this threshold(s) is complex and is explored 
further in the section below. The new rule must endorse one or more specific methodologies for 
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predicting a patient’s prognosis that are accessible to primary care physicians nationally. The 
prognostic method must be applicable to a large population (e.g., community-dwelling older U.S. 
adults) and provide estimations of life expectancy over at least as many years as the life 
expectancy threshold. For example, a 4-year prognostic index is no help for a screening rule 
that requires 10 years of life expectancy to recommend screening. Finally, the prognostic 
method must rely on data which are readily available in the outpatient setting. 
Second, the prognostic method(s) endorsed by the new rule must be sufficiently 
accurate within a development cohort, as measured by discrimination and calibration in 
prospective cohort trials. Discrimination, or the ability of a prediction model to separate those 
who will have a certain outcome from those who will not, is a key performance measure of such 
models. The most popular means of expressing discrimination is the c statistic, expressed 
graphically as the area under a receiver operating characteristic (ROC) curve.57, 58 Wald and 
Morris also describe a unique tool for graphically representing discrimination, the Risk-
Screening Converter, which is available online.59 Discrimination by itself does not describe the 
value of a prediction model, however, because a model with good discrimination (high c 
statistic) may still be useless if the threshold for recommending screening is outside the range of 
predictions provided by the model.5860 A second performance measure, calibration, is also 
important. Calibration measures agreement between predicted outcomes and observed 
outcomes, and may be described by the y-intercept and slope of a calibration plot or the 
Hosmer-Lemeshow goodness-of-fit test.58  
Minimum acceptable levels of discrimination and calibration will need to be established. 
In their review of the accuracy of prognostic indices, Yourman and colleagues describe a 
scoring system for discrimination from “poor” to “excellent” based on C-statistics2, but they do 
not indicate what score constitutes acceptable discrimination. In the case of calibration, 
Yourman et al. propose that 10 or more percentage points’ difference between predicted and 
observed mortality constitutes poor calibration, and fewer than 10 percentage points’ difference 
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is good calibration. Final “passing scores” for these performance characteristics may require 
consensus from expert clinicians, and be considered in the context of other features the 
prognostic method. Even a prognostic method(s) with moderate to good overall accuracy may 
be suitable for use if it helps to move patients above or below a threshold and facilitates 
decision making. 
Third and importantly, the prognostic method(s) must be accurate not only in a 
development cohort, but generalized to other groups. Demonstrating generalizability may be a 
particular challenge for life expectancy prediction methods because life expectancy varies 
greatly between subpopulations in the United States such as ethnic groups and socioeconomic 
groups, and the risk factors predicting life expectancy may vary as well. Furthermore, the 
relative predictive value of risk factors for death other than age may decline as a patient’s age 
increases, so the ages of individuals in the development cohort may also limit generalizability. It 
may not be possible to expect one prediction method to perform adequately for all U.S. older 
adults, but the limits of their demonstrated utility should be explicitly defined; for example, 
prognostic index for adults older than 70 y.o. residing in nursing homes. Yourman and 
colleagues2 break down the generalizability of prognostic indices into two factors, reproducibility 
and transportability. Reproducibility is demonstrated by first developing the index in a 
development cohort, then validating it in multiple “bootstrap” samples generated from the same 
development cohort with replacement (data resampling). Transportability is demonstrated by 
validating the index in a validation cohort that differs from the development cohort by some 
major variable, and is the more valuable measure. Validation cohorts may differ from 
development cohorts by variables such as geography, calendar time, method of data collection, 
types and level of progression of disease, follow-up interval, or others.2 
Fourth, the application of the new rule compared to current practice (or the old rule) in 
large populations should produce substantial reclassification; which is to say, large numbers of 
individuals should be moved from the screening-recommended group to the screening-not-
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recommended group and vice versa. Reclassification is a relatively new measure of a risk 
stratification scheme that can quantify its improvement over an existing scheme, which may give 
an indication of whether clinical outcomes are likely to change under application of the new 
scheme. In the case of cancer screening, the choice of comparison rule for calculating 
reclassification is very important. While the simplest comparator is an age-based screening rule, 
it’s important to remember that current practice is heterogeneous and likely more sophisticated. 
For instance, even physicians who generally stop recommending screening after a certain age 
are likely to make reasonable exceptions to this rule for patients with obviously poor prognoses. 
One drawback to using current screening rates as the basis for calculating reclassification is 
that other factors besides age and health (patient preferences, ability to pay, other priorities, 
etc.) affect screening decisions in current practice, and the influence of these factors under the  
new rule may be hard to model. 
Numerous methods for calculating reclassification have been proposed, such as 
reclassification tables, net reclassification improvement (NRI) indices, and the closely related 
integrated discrimination improvement (IDI) indices,57 among others. The NRI index utilizes 
reclassification tables and considers that movement of individuals who have an event (death) 
into higher risk categories and movement of individuals who do not have an event into lower risk 
categories constitute improved classification, and presents the proportion of individuals moving 
as a single sum. In clinical practice, however, physicians and patients may not believe that 
reclassification “up” (e.g., from a don’t-screen group to a screen group) and “down” (from a 
screen group to a don’t-screen group) have the same value. Because no classification scheme 
is perfect, some individuals in the don’t-screen group will in fact end up living for many decades, 
and some in the screening group will in fact die before they have an opportunity to benefit from 
screening. In clinical practice, patients and physicians may weigh these two types of error 
differently, though there may be disagreement as to which represents the worse scenario. 
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Importantly, if consensus can be reached, the NRI calculation can be weighted to represent 
different values for movements “up” or “down” in categories.61 
Fifth, after the potential for substantial reclassification has been demonstrated, there 
should be a demonstration that clinical outcomes will improve with implementation of the new 
rule. This step is an important validation of the evidence for the first four criteria. If a new 
prediction method is not accurate and generalizable enough, some individuals may be 
inappropriately reclassified into screen or don’t-screen groups, and clinical outcomes may not 
improve. Ideally, a large randomized controlled trial should be conducted in which individual 
physicians or clinics are randomized to two groups. One group is trained to use a life 
expectancy prediction method to decide whether or not to recommend a cancer screening to 
their older patients. The other group is told to continue their regular practice, or else is trained to 
use a simple age threshold (“old rule”) to guide their screening recommendations. The older 
patients involved should be followed for many years with periodic measurements of clinical 
outcomes. Choice in outcomes should reflect both potential benefits of screening (life-years 
gained through early detection and treatment of cancer) and potential harms of screening 
(physical harm, emotional concern, hassle, and financial costs resulting from the screening 
cascade). Although the weighting of these potential harms and benefits against each other is 
controversial, the trial should generally show an improvement in the benefit-to-harm ratio 
experienced by patients in the “new rule” group compared to the “old rule” or current practice 
group. Such a trial may require many years or decades to accumulate outcomes, but constitutes 
an important component of the evidence for the new rule. 
Sixth and finally, the potential improvement in clinical outcomes resulting from the new 
rule must be balanced against the costs and feasibility challenges to its implementation, 
including burden on physicians. Financial costs resulting from implementation of the new rule 
may include education and training of physicians to use a new prognostic method, costs 
associated with gathering any clinical information needed for prognostication that isn’t readily 
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available, and if the new rule results in higher overall screening rates, the costs of increased 
screening, work-up, and treatment for cancer. Feasibility issues are likely to include the 
additional time and demands on physicians’ memories needed to discuss life expectancy during 
busy outpatient clinic interactions, as well as engendering the public’s trust in the new rule and 
measuring the quality of its implementation. Ideally, a cost-effectiveness analysis would 
demonstrate that new rule is cost-effective at the life expectancy threshold chosen for 
recommending screening, such as the one demonstrated by Wald, Simmons, and Morris for 
CVD risk screening using age alone versus multiple risk factors plus age.62 
 
Addressing a life expectancy threshold for screening 
 As discussed previously, if a life expectancy based rule for stopping cancer screening is 
endorsed by a guideline development group (GDG), a life expectancy threshold or thresholds 
will need to be chosen. GDGs such as the breast cancer GDGs of the American Cancer 
Society21 and American Geriatrics Society22 have endorsed life expectancy thresholds around 
the five year mark for breast cancer based on the separation of survival curves for screened and 
unscreened populations in randomized controlled trials.17 However, the separation of survival 
curves merely indicates the point at which the probability that a patient will benefit from cancer 
screening is greater than zero. The absolute probability of benefit may still be quite small and 
must also be balanced against the probability of harms from the screening test and any 
downstream interventions including work-up, diagnosis, and treatment. Therefore, depending 
how one values these benefits and harms, it may be reasonable to conclude that a life 
expectancy much greater than five years is needed to achieve net benefit from the screening 
intervention, where net benefit is defined as benefits minus harms. 
 To explore the threshold issue further, let us consider an 80 y.o. woman of average 
health considering whether to continue mammography. There are multiple ways she may 
benefit from the mammogram, including reduced risk of breast cancer mortality, reduced risk of 
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physical and psychological suffering from advanced breast cancer, and reassurance from a 
negative mammogram. The most important benefit is reduced risk of mortality. Of eight 
randomized controlled trials of screening mammography, only one enrolls older women up to 
age 74.13 Among women aged 65-74 at the beginning of this trial, the following absolute 
mortality reductions are seen between screened and unscreened groups at the following time 
points:  
Years after 
randomization 
Reduced breast cancer-specific 
mortality per 1000 screened 
8 years 0.45 
12 years 1.25 
16 years 1.87 
Table 7. Difference in breast cancer specific mortality between 65-74 y.o. women invited to a 
breast cancer screening program and women not invited. Adapted from Nystrom et al. 2002.42 
 
These data indicate that the absolute probability of benefiting from mammography remains 
small out as far as 16 years. It is also important to consider that the magnitude of the benefit the 
woman may receive from a potential cancer caught and treated early, measured in life-years 
gained, is limited by her life expectancy. Imagine a “best case scenario” for this 80 y.o. woman; 
namely, a mammogram performed at age 80 detects, and surgery successfully treats, a cancer 
that would have otherwise gone undetected and resulted in her death at age 85. The average 
life expectancy of an 80 y.o. woman is 9.4 years;25 therefore, the mammogram has extended 
her life, but only by about four years. The likelihood of this happening, based on interpolation of 
the data above, is about 1 in 1000. 
 The magnitude and likelihood of this benefit must be weighed against the likelihood and 
magnitude of the harms this patient may suffer as a result of screening. As discussed in the 
introduction, these harms may be physical or psychological and may result from the 
mammogram itself or any aspect of the screening cascade, including work-up of true or false 
positives, diagnosis including overdiagnosis, and treatment such as surgery, radiation therapy, 
and chemotherapy. The harms may be minor or serious including death. Although false positive 
as well as false negative mammography results are observed to decrease with age,13 other 
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harms increase with frailty and age-related comorbidities. For example, perioperative 
complications are more likely in older adults in general, especially those with heart disease and 
other comorbidities.63 Likewise, mammography and follow-up procedures may be especially 
burdensome or frightening to women with cognitive or functional impairment.13 The likelihood of 
each of these various harms must be considered and is difficult to generalize. 
 Considering the limitations of potential benefits and importance of potential harms in 
older adults, it may be reasonable to choose a life expectancy threshold of 10, 15, or even 20 
years for recommending a particular cancer screening. Reaching consensus as to the 
appropriate threshold will be a challenge. Because this issue is so value laden and potentially 
sensitive, an ideal means of reaching consensus would involve the input of patients and patient 
advocates. One way this could be accomplished is by a qualitative research project involving a 
diverse group of older adults. The older adults should receive training on the potential benefits 
and harms of a particular type of cancer screening. They should then engage in a discussion 
about which particular benefits or harms are most important to them, and what threshold feels 
the most appropriate. The results of this research should be conveyed back to the guideline 
development group, which would ideally have at least one patient representative in its 
membership. 
 Several formal methodologies have been published for helping groups reach consensus 
on a challenging topic. Fink and colleagues describe four of these in their 1984 paper on 
consensus methods.64 Among these, the Delphi method and nominal group method have been 
in practice for at least four decades and involve multiple rounds of input from experts in a field. 
Following to the Delphi method, experts in cancer screening or primary care could be sent 
individual surveys soliciting their opinions on life expectancy thresholds, which would then be 
collected, tabulated, and reported anonymously to the group. The group would continue to 
provide survey feedback through a total of 3-4 rounds until consensus on a single threshold or a 
point of diminishing returns is reached. Following the nominal group method, a panel of experts 
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could be brought to a structured meeting at which each individual records her own opinions then 
presents them to the group in a round robin way for debate. Multiple rounds are repeated until 
consensus, in particular a rank order list of life expectancy thresholds, is reached. 
 The guideline development groups will also need to decide whether they will consider 
costs in their analysis. The use of economic arguments to limit health care is very controversial, 
and in particular their application to services for older adults may lead to accusations of ageism 
and rationing at the expense of a vulnerable population. At the same time, the overuse of 
services is a leading cause of unsustainable health care costs in the United States.65 Reducing 
the use of screening services that are unlikely to benefit patients while still causing harms is one 
intervention which may simultaneously reduce costs and improve the quality of health care for 
older adults. 
Conclusion 
 Deciding when to stop cancer screening in older adults is a complex task. Using a life 
expectancy screening rule, as opposed to an age-based screening rule, is appealing for its 
potential to discriminate better between individuals who may achieve net benefit from cancer 
screening from those who will not. It may be considered part of a more individualized approach 
to medical decisions, an appealing trend in health care. On the other hand, evidence for an 
accurate, precise, and widely applicable method for predicting life expectancy is lacking, and if it 
were present, the need to calculate life expectancy for individual patients will place a time and 
memory burden on physicians. An important criterion for evaluating the evidence for a new 
screening rule is reclassification, reflecting the incremental improvement of the new rule over an 
existing screening rule. A total of six criteria for evaluating the evidence for a new rule are 
proposed in this paper. Guidelines for stopping cancer screening should not promote 
widespread use of life expectancy predictions until there is sufficient evidence to satisfy these 
criteria.  
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APPENDIX A. Search Strategies 
 
MEDLINE Search String 
(“Life Expectancy” OR “mortality risk”) AND (“Nursing Home*” OR outpatient* OR hypothetical 
OR "paper patient" OR vignette*) AND (Forecasting OR prediction OR predicting OR prognostic 
OR prognosis) 
 
EMBASE Search String 
('life expectancy'/exp OR 'life expectancy' OR 'mortality risk') AND ('nursing home'/exp OR 
'nursing home' OR 'home care'/exp OR 'home care' OR 'outpatient care'/exp OR 'outpatient 
care' OR 'outpatient'/exp OR 'outpatient' OR 'vignette'/exp OR 'vignette') AND ('prediction and 
forecasting'/exp OR 'prediction and forecasting' OR 'predict' OR 'predicting' OR 'prognosis'/exp 
OR 'prognosis') AND ([embase]/lim OR [embase classic]/lim) 
 
PsycINFO Search String 
((DE "Life Expectancy") OR "mortality risk") AND ((DE "Prediction")  OR  (DE "Prognosis") OR 
"forecasting")  
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APPENDIX B. Quality Assessment Charts for Included Studies 
Study citation: Clarke MG, Ewings P, Hanna T, Dunn L, Girling T, Widdison AL. How accurate are doctors, nurses 
and medical students at predicting life expectancy? Eur J Intern Med. 2009;20(6):640-644. 
Source of potential 
problem 
Internal or External 
Validity? 
Description of potential problems 
Patient Vignette/Assessment Characteristics  
Patient demographics External validity Mean age of 68 (range 55 to 82) years. Mean adjusted actuarial 
LE of 11.6 (range 2 to 28) years. “Designed to represent a sample 
of patients that would commonly be encountered in…outpatient 
clinics.” 
Prevalence, severity of 
patient comorbidities 
External validity, 
Internal validity 
Not described. 
“Examples” of conditions in vignettes – angina pectoris, atrial 
fibrillation, cardiac failure, hypertension, myocardial infarction, 
peripheral vascular disease, surgery (cardiac/vascular), valvular 
disease, asthma, COPD, DM (type 1 or 2), thyroid disease, 
pituitary disease, cerebrovascular disease, epilepsy, depression, 
myeloma, obesity, renal failure. 
Level of detail of 
vignettes 
External validity Vignettes included patient age, sex, and brief PMH (various 
common medical conditions, some or all comment briefly on 
severity of illness). 
Sample vignette: 
“66 year old male; poorly controlled insulin dependent diabetic 
with retinopathy, hypertension (BP 170/95) and high cholesterol 
(on simvastatin.” 
Number of patients 
represented 
Internal validity 57 patient vignettes + 13 duplicate vignettes = 70 total vignettes  
Choice and Application of Reference Standard for LE (e.g., actuarial LE) 
Appropriateness of 
reference standard 
Internal validity Reference standard: LE derived from actuarial tables and 
adjusted for comorbidities using mortality ratios assigned to 
comorbidities by two major insurance companies. “Standard” LE 
was derived from Government Actuary Department’s 2001-2004 
interim life tables (unsure if for United Kingdom, England, or other 
geographical area), then adjustments based on the hypothetical 
patient’s comorbidities were made using a reference book of 
adjustment factors used in the life insurance industry 
(Brackenridge’s Medical Selection of Life Risks, 5
th
 ed.). 
Sophistication of 
reference standard 
Internal validity Accounts for comorbidities by assigning a numerical rating, 
expressed as a percentage of standard mortality. Life insurance 
companies determine the ratings, based on a variety of sources of 
information including companies’ own experience, reviews of 
medical literature, and the opinion of clinicians.  
Clinician recruitment, characteristics 
Sample size of clinicians Internal validity 40 providers or future providers, only 2 practicing generalists. 
20 physicians (2 GPs, 2 specialists, 7 anesthetists, 9 surgeons), 
20 nurses (medical, surgical, oncological), and 20 medical 
students (4
th
-5
th
 year) 
Subject selection External validity Source population: physicians, nurses, and medical students in 
the United Kingdom (region, hospital(s), department(s), etc. 
unspecified) 
 
Selection of subjects: Volunteers. Recruitment not described. 
Potential refusals or dropouts not described. 
Clinician characteristics External validity Demographics, type of practice, and length of clinical experience 
not described. 
Assessment Methods 
Assessment 
administration 
Internal validity, 
External validity 
Subjects had unlimited time to read the vignettes and assign a 
predicted LE. Vignettes were presented in a random order. Setting 
in which the assessment was delivered and monitoring for 
“cheating” was not reported. 
Overall potential for Internal validity Moderate. 
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measurement bias Specifics for how the assessment tool was administered and 
scored were not reported, except that the vignettes were 
randomized. Otherwise, no potential biases noted. 
Outcomes and Analysis 
Handling of incomplete 
responses 
Internal validity Not reported. 
Other analysis problems Internal validity  
Overall internal validity (good/fair/poor): Fair 
Major limitations moderate amount of patient information 
described in vignettes and unclear performance of the reference 
standard for life expectancy. 
Overall external validity (good/fair/poor): Fair - Poor 
Small sample size (n=20 physicians). Sample subjects only 
include 2 general practitioners who likely make cancer screening 
decisions. The degree to which inferences about the other 
clinicians’ and students’ performances may be made applied to 
PCPs is unclear. Lack of information about recruitment is also 
limiting – these subjects may have volunteered because they felt 
confident in their ability to predict LE, or because they were part of 
some unnamed academic program that makes them different from 
other clinicians. The patient vignettes do, however, appear to 
represent the types of older adult outpatients who would be 
subject to difficult cancer screening decisions. 
Comments: 
Results 
Outcomes measured: subject accuracy, precision (RMSE), and consistency including intra-observer reliability and 
inter-observer reliability; comparison among 3 types of subjects 
 
Overall, subjects underestimated LE by 1.83 (2.47-1.19) years. Overall intra-observer reliability was 0.88, inter-
observer reliability was 0.60. Regarding precision, overall RMSE was 4.99 (4.71 to 5.28) years. Subjects 
underestimated 64% of the time, overestimated 27% of the time, and were correct (to the year??) 9% of the time. 
 
For physicians, mean predicted LE was underestimated by 1.46 (2.61 to 0.31) years cf. actuarial LE. Intra-observer 
reliability was 0.91, inter-observer reliability 0.66. Physicians mean predicted LE was 10.2 years vs. mean adjusted 
actuarial LE of 11.6 years. 40% of physicians had a statistically significant tendency to become more inaccurate as 
actuarial LE increased. 
 
Physicians were most accurate in their predictions, followed by nurses then medical students. The differences in 
accuracy between groups were not statistically significant, however. 
 
While the authors conclude that the subjects are inaccurate, imprecise, and inconsistent (good intra-observer, poor 
inter-observer) in their prediction of LE, the physician group as a whole only underestimated LE by 1.46 (2.61 to 0.31) 
years (granted, this error increased as years of LE increased). In terms of clinical decision making about cancer 
screening, this average error may have low clinical significance. 
 
Study citation: Krahn MD, Bremner KE, Asaria J, et al. The ten-year rule revisited: Accuracy of clinicians' estimates 
of life expectancy in patients with localized prostate cancer. Urology. 2002;60(2):258-263. 
Area of potential 
problem 
Internal or External 
Validity? 
Description of potential problems 
Patient Vignette/Assessment Characteristics  
Patient demographics External validity Males age 55, 65, or 75 with moderately aggressive clinically 
localized prostate tumors (Gleason score and PSA given) – 
physicians were instructed to disregard this cancer when 
estimating LE 
Prevalence, severity of 
patient comorbidities 
External validity, 
Internal validity 
Three scenarios: 
(1) no comorbid illness or functional impairment (Index of 
Coexistent Disease = 0) 
(2) MI 5 years ago; angina with one flight of stairs; on ASA, β-
blocker, and nitrates followed by cardiologist (ICED = 2) 
(3) symptomatic COPD w/ SOB when brushing teeth or getting 
dressed; recurrent lung infections; MI 5 yrs ago; angina with one 
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flight of stairs; on ASA, CCBs, nitrates, and ipratropium (ICED = 3) 
--Depending on age and comorbidity, model-predicted LE ranged 
from approx.1.8 years to 22 years. 
Level of detail of 
vignettes 
External validity See vignette language above. 
Number of patients 
represented 
Internal validity 18 vignettes: 2 prostate cancer patients, each with 3 ages and 3 
levels of comorbidity 
--“Most” of the urologists (?% - 115 responders) were sent only 9 
vignettes (one prostate cancer patient with 3 ages and 3 levels of 
comorbidity) based on calculations of sample size needed for 
statistical power 
--All radiation oncologists received 18 vignettes 
Choice and Application of Reference Standard for LE (e.g., actuarial LE) 
Appropriateness of 
reference standard 
Internal validity Two-state (living, dead) Markov model created by group. Two 
variables – age, comorbidity (all males). Age-adjusted LE from 
Statistics Canada life tables. Comorbidities were related to ICED 
levels. Data from a cohort of men with conservatively treated 
prostate cancer and various ICED levels were used to calculated 
annual HR of dying for each ICED level. The model ultimately 
determined an average LE and 95% CI for each vignette patient. 
Sophistication of 
reference standard 
Internal validity Accounted for age, male gender, and comorbidity score. 
Clinician recruitment, characteristics 
Sample size of clinicians Internal validity 310 physicians initially surveyed  277 eligible for study and 
having contact info 
Of these, 191 respondents (69% response rate; 138 urologists, 53 
rad oncologists) 
Subject selection External validity Source population: urologists and radiation oncologists actively 
seeing prostate cancer patients in Canada 
 
Study population: members of the college of Physicians and 
Surgeons of Ontario actively practicing in adult urology OR 
radiation oncologists registered with the Ontario Cancer Institute 
currently treating genitourinary cancers 
 
All members of the study population were surveyed by facsimile. 
Subjects were excluded they could not be reached (n=13), had 
retired (n=6), or did not see patients with prostate cancer (n=14). 
Clinician characteristics External validity 53 Radiation oncologists: 15.1% women, 50% graduated from a 
Canadian university  
138 Urologists: 2.2% women, 70% graduated from Canadian 
university 
Years of clinical experience not named. 
Assessment Methods 
Assessment 
administration 
Internal validity, 
External validity 
Survey questionnaire delivered to subjects by facsimile. They 
were asked to return by facsimile. 2
nd
 copy sent if no response in 
2 wks. Nonresponders then received questionnaire in mail with 
stamped/addressed return envelope.  
Cannot know if the subjects used resources to choose their 
responses, or how much thought and effort they put into 
responses. 
Overall potential for 
measurement bias 
Internal validity Moderate 
Outcomes and Analysis 
Handling of incomplete 
responses 
Internal validity Response rate of 69%. Do not report numbers of incomplete 
surveys, but at least 4 surveys were incomplete. 
Other analysis problems Internal validity Study does not report actual numbers for overestimation or 
underestimation of LE estimates, only graphical data. However, a 
complete data set was obtained from the study authors. 
Overall internal validity (good/fair/poor): Fair 
Concerns include unsupervised completion of assessments 
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(sent/returned by fax). The accuracy of the reference standard is 
unclear (although it does appear to be sophisticated and includes 
confidence intervals. Reporting of results in the paper is poor, but 
I was able to obtain complete results by correspondence with the 
study authors. 
Overall external validity (good/fair/poor): Fair 
The study population is subspecialists and not likely involved in 
cancer screening decisions. Their ability to predict LE may be 
somewhat representative of primary care providers, however, as 
they are also physicians.  
The vignettes do appear to represent the types of older adult 
outpatients who would be subject to difficult cancer screening 
decisions, particularly the 65 yo and 75 yo patients. 
Comments: 
Although this study was limited the patient scenarios to early stage prostate cancer patients, in their assessment they 
instructed physicians not to consider prostate cancer mortality but rather LE due to comorbidities. They were 
particularly interested LE less than or greater than 10 years, because this was their cutoff for recommending 
prostatectomy. They conclude that clinicians have “sufficient accuracy [at LE prediction] to use the 10-year rule.” 
 
31% of physicians’ predictions were within +/- 1 year of model-predicted LE, 48% were within 2 years, and 67% were 
within 3 years. The RMSE for the physicians’ estimates ranged from 2.4 to 5.2 years, depending on the vignette. 
When asked to predict 10-year survival (yes/no), physicians were correct 82% of the time. Clinicians’ error increased 
by 1.08 years per year of the model’s prediction. Neither patient age nor comorbidity are associated with physician 
error, however. 
 
Other outcomes assessed:  
--Choice of initial prostate cancer therapy for patients (radical prostatectomy, radiation, or watchful waiting) 
 
Results (obtained via correspondence with authors) 
 
  Comorb 
Model-
predicted LE 
(yrs) 
Dr-
predicted 
LE (yrs) 
Dr std 
dev (yrs) 
Dr range 
(yrs) 
Difference btw 
drs and model 
(yrs) 
Over or 
under? 
Age 
55 
ICED=0 22 23.726 3.867 10, 35 1.726 over 
ICED=2 14.5 12.18 4.548 3.5, 30 -2.32 under 
ICED=3 6.3 7.291 3.384 1, 20 0.991 over 
Age 
65 
ICED=0 15 16.174 3.474 10, 30 1.174 over 
ICED=2 8.9 7.996 3.152 3, 20 -0.904 under 
ICED=3 3.2 4.948 2.6 0, 15 1.748 over 
Age 
75 
ICED=0 9 8.904 3.165 1, 25 -0.096 under 
ICED=2 5 4.601 2.932 0, 25 -0.399 under 
ICED=3 1.8 2.982 1.747 0, 12.5 1.182 over 
     
MEAN 0.345 over 
 
 
Study citation: Lewis CL, Moore CG, Golin CE, Griffith J, Tytell-Brenner A, Pignone MP. Resident physicians' life 
expectancy estimates and colon cancer screening recommendations in elderly patients. Med Decis Making. 
2008;28(2):254-261. 
Area of potential 
problem 
Internal or External 
Validity? 
Description of potential problems 
Patient Vignette/Assessment Characteristics  
Patient demographics External validity Women ages 75 or 85 with 3 levels of health status 
Prevalence, severity of 
patient comorbidities 
External validity, 
Internal validity 
3 levels of comorbidity intended to represent good, fair, and poor 
health status for age. The vignettes were reviewed and edited by 
12 researchers and physicians in attempt to refine health status 
designation. 
Level of detail of External validity Include age, gender, comorbidities with reference to their severity, 
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vignettes and description of functional status (3-4 sentences total) 
Example: “Mrs. Perry is a 75-year-old woman with chronic 
obstructive pulmonary disease and well-controlled hypertension. 
She has severe osteoarthritis in both knees, which limits her 
ability to walk outside her house. She experiences shortness of 
breath with activities only when she does not take her inhalers.” 
(fair health status) 
--For the 85 y.o. patient vignettes, subjects were provided with life 
tables indicating median LE for age and health state. The subjects 
did not have access to this information for the 75 y.o. patient 
vignettes. 
Number of patients 
represented 
Internal validity 3 unique vignettes, repeated for women age 75 vs. age 85, for 6 
total vignettes 
Choice and Application of Reference Standard for LE (e.g., actuarial LE) 
Appropriateness of 
reference standard 
Internal validity Appropriate. Used framework suggested by Walter & Covinsky 
(2001). Used LE determined by National Center for Health 
Statistics 1997 Life Tables of the United States, divided by 
quartiles of LE for each age and gender. 
Sophistication of 
reference standard 
Internal validity Did not consider influence of specific comorbidities, but rather 
estimated overall health as falling into the top 25%, middle 50%, 
or bottom 25% of United States adults. 
--Variables considered: age, gender, quartile of health 
Clinician recruitment, characteristics 
Sample size of clinicians Internal validity 50 resident physicians 
Subject selection External validity Residents were approached to participate during their outpatient 
clinics or during a conference unrelated to CRC screening 
--77 residents were eligible, 52 were available during the 
recruitment period, 50 agreed to participate 
Clinician characteristics External validity Internal medicine residents at University of North Carolina in Oct-
Nov 2005; preliminary residents and Medicine-Pediatrics residents 
on their Pediatric rotations were excluded 
--50% female 
--Mean age 29 
--73% White, 20% Asian or Am Ind, 4% Af-Am, 2% Hispanic 
Assessment Methods 
Assessment 
administration 
Internal validity, 
External validity 
Very detailed methods. Internal medicine residents were 
approached during either their outpatient clinics or during a 
conference. Some exclusions applied. Questionnaire took 10 
minutes. The authors precisely describe exact questions asked 
and the order they were presented, as well as appropriate 
rationale for their choices. 
Overall potential for 
measurement bias 
Internal validity Low – Moderate 
Outcomes and Analysis 
Handling of incomplete 
responses 
Internal validity No incomplete responses reported. 
Other analysis problems Internal validity -- 
Overall internal validity (good/fair/poor): Fair - Good 
Very thorough reporting of methods, including description of all 
parts of the questionnaire and rationale for choices of questions. 
High response rate (96%). The survey appears to have been 
applied fairly. The reference standard is reasonably sophisticated, 
although the precision may be somewhat limited due to the 
approximation of health status into quartiles. 
 
Overall external validity (good/fair/poor): Fair 
The same size is modest and the sampling method is a 
convenience sample at a single institution; however, a high 
response rate is achieved.  As resident physicians, subjects are 
early in their medical training and may or may not perform 
differently from more experienced clinicians. All are in a specialty 
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where they would be expected to make cancer screening 
decisions. 
The vignettes are reasonably detailed and appear to represent the 
type of older adults who would be subject to difficult cancer 
screening decisions. A limited number of vignettes were available 
(6 vignettes, 3 scenarios x 2 ages). The residents may perform 
differently for patients of different ages, clinical scenarios, or 
gender. 
 
 
Results: 
LE prediction 75 y.o. poor health 
(actuarial LE 7 yrs) 
75 y.o. fair health 
(actuarial LE 12 yrs) 
75 y.o. good health 
(actuarial LE 17 yrs) 
 < 2 yrs 16% 0% 0% 
2 – 5 yrs 42% 6% 0% 
5 – 10 yrs 42%  *correct* 92% 28% 
> 10 yrs 0% 2%   *correct* 72%   *correct* 
 85 y.o. poor health 
(actuarial LE 3yrs) 
85 y.o. fair health 
(actuarial LE 6 yrs) 
85 y.o. good health 
(actuarial LE 10 yrs) 
 < 2 yrs 58% 14% 0% 
2 – 5 yrs 34% 44% 8% 
5 – 10 yrs 8% 42% 90% 
> 10 yrs 0% 0% 2% 
 
Additional results: 
--When subjects were asked whether they would recommend screening for each of the 75 y.o. vignette patients, their 
recommendations varied appropriately with their predicted LE, with fewer recommendations for screening as 
predicted LE decreased. However, a broad range of screening recommendations was still observed for patient 
vignettes with medium LE (2-5 yrs and 5-10 yrs).  
--High proportion of subjects reported uncertainty in their recommendation (range: 48-86%, depending on vignette). 
 
Study citation: Walz J, Gallina A, Perrotte P, et al. Clinicians are poor raters of life-expectancy before radical 
prostatectomy or definitive radiotherapy for localized prostate cancer. BJU Int. 2007;100(6):1254-1258. 
Area of potential 
problem 
Internal or External 
Validity? 
Description of potential problems 
Patient Vignette/Assessment Characteristics  
Patient demographics External validity Males, mean age 65.8 yrs (range 55-83 yrs), 40% had died at 10 
yrs; all had prostate cancer and were treated with RT or 
prostatectomy without recurrence (subjects instructed to disregard 
prostate cancer in predictions) 
Prevalence, severity of 
patient comorbidities 
External validity, 
Internal validity 
Real patient data was converted to Charlston Comorbidity Index 
(CCI) scores. The median score was 2, range 0-9. 40% of patients 
died within 10 years; mean actual survival was 10.3 years. 
Level of detail of 
vignettes 
External validity Low-moderate 
Included male gender, age, individual comorbidities (no mention 
of severity of the comorbidity), and CCI score. 
Number of patients 
represented 
Internal validity 50 vignettes based on real patient data 
Patient data selection: 
--Used real patient data from a random sample of Quebec Health 
Plan patients (sole insurer in Quebec province) 
--Of 17,570 pts diagnosed w/ prostate ca by ICD-9 code between 
1/1/1989 – 12/31/2000; patients who had secondary therapy for 
prostate cancer or < 10 yrs of f/u were excluded, and then 50 
were randomly selected (25 who received RT and 25 who 
received surgery) 
--Patient comorbidities and vital status were obtained from ICD-9 
codes 
Choice and Application of Reference Standard for LE (e.g., actuarial LE) 
Appropriateness of 
reference standard 
Internal validity Appropriate. Data from patients treated for prostate cancer with 
real follow-up to 10-year survival. 
Sophistication of Internal validity Low. Information about the patients’ comorbidity was likely very 
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reference standard limited, as only ICD-9 codes were available, and presumably did 
not convey any information about the severity or control of 
disease states. 
Clinician recruitment, characteristics 
Sample size of clinicians Internal validity 19 physicians, residents, and students 
Subject selection External validity Not mentioned 
Clinician characteristics External validity 6 urologists, 10 residents (? specialty or year in training), 3 
medical students in last year of training. No further demographics. 
Assessment Methods 
Assessment 
administration 
Internal validity, 
External validity 
Not mentioned. 
Overall potential for 
measurement bias 
Internal validity Moderate-poor 
Outcomes and Analysis 
Handling of incomplete 
responses 
Internal validity Not mentioned. 
Other analysis problems Internal validity -- 
Overall internal validity (good/fair/poor): Fair - Poor 
Major concerns: There is no mention of how the questionnaires 
with patient vignettes were administered. While subjects were 
provided with a list of ICD-9 coded patient comorbidities, they 
presumably had no information about the severity or control of the 
patients’ diseases. Furthermore, the ICD-9 codes may have been 
outdated or missing for some patient comorbidities. 
Advantages to these authors’ use of real patient data does include 
side-by-side comparison of actual patient survival to actuarial 
survival probability to clinician-predicted patient survival.  
Overall external validity (good/fair/poor): Fair-Poor 
The sample size is very small and there is no reporting of subject 
selection or of subject demographics, so we cannot know if they 
are representative of other physician groups. With regard to 
cancer screening decisions, there are no primary care providers 
included in this study. There is no information as to the career 
paths of the resident or student participants. 
 
The vignettes do appear to represent the types of older adult 
outpatients who would be subject to difficult cancer screening 
decisions, as mean survival is around 10 years (a cutoff significant 
for cancer screening). 
 
Results 
Authors provide side-by-side comparison of actual patient survival to actuarial-predicted patient survival to clinician-
predicted patient survival. 
Percent of all patient vignettes surviving to 10 years: 
      Actual survival – 60.0% of patients 
      Mean actuarial survival probability – 57.3% (?of patients) 
      Subject-predicted survival – 46.0% of patients (range: 20.0% to 70.0%) 
 
For all subjects combined (n=19), AUC for the ROC (c-statistic) for predicting 10-yr survival was a mean and 95% CI 
of 0.68 (0.64-0.71) 
      For urologists: 0.67 (0.60-0.72), n = 6 
      For residents: 0.69 (0.64-0.74), n = 10 
      For medical students: 0.67 (0.58-0.76), n = 3 
 
Study citation: Wilson JR, Clarke MG, Ewings P, Graham JD, MacDonagh R. The assessment of patient life-
expectancy: How accurate are urologists and oncologists?. BJU Int. 2005;95(6):794-798. doi: 10.1111/j.1464-
410X.2005.05403. 
Area of potential 
problem 
Internal or External 
Validity? 
Description of potential problems 
Patient Vignette/Assessment Characteristics  
Patient demographics External validity Males 55-82 y.o; designed to represent “patients seen in a 
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general urology clinic” 
Prevalence, severity of 
patient comorbidities 
External validity, 
Internal validity 
Median (range) actuarial chance of 10-yr survival is 70 (5-94)% 
Level of detail of 
vignettes 
External validity Moderate 
Age and medical history; example vignettes: “66 y.o. man with 
poorly controlled insulin-dependent DM, diabetic retinopahy, HTN 
and hypercholesterolemia”; “67 y.o. man with mild asthma” 
Number of patients 
represented 
Internal validity 57 unique vignettes and 13 repeated vignettes 
Choice and Application of Reference Standard for LE (e.g., actuarial LE) 
Appropriateness of 
reference standard 
Internal validity LE derived from actuarial tables and adjusted for comorbidities 
using an actuarial “numerical rating system” (Brackenridge’s 
Medical Selection of Life Risks, 5
th
 ed.). Comorbidity factors were 
summed.  
--The Charlson index was applied to comorbidity-attunded age to 
derive 10-year mortality risk. 
Sophistication of 
reference standard 
Internal validity Accounted for age, male gender, type of comorbidity, and (to 
some degree) severity of comorbidity. 
Clinician recruitment, characteristics 
Sample size of clinicians Internal validity 18 physicians  
Subject selection External validity Poor. No mention of how subjects were selected. 
Clinician characteristics External validity 4 urologists, 2 oncologists, 4 “urology specialist registrars,” 4 
surgical senior house officers, 4 surgical pre-registration house 
officers 
--No mention of years of experience (except to say “varying 
seniority”) or other demographics 
--No mention of geographic location or academic affiliation 
Assessment Methods 
Assessment 
administration 
Internal validity, 
External validity 
“Nature of study” explained to subjects. Survey was supervised. 
No time constraint. 
Overall potential for 
measurement bias 
Internal validity Moderate 
Outcomes and Analysis 
Handling of incomplete 
responses 
Internal validity Not reported. 
Other analysis problems Internal validity  
Overall internal validity (good/fair/poor): Fair 
Although the methods section is brief, the survey seems to have 
been applied fairly. The reference standard appears to be 
reasonably sophisticated, but subject to errors inherent in the 
model. This potential error was not discussed in detail. 
 
Of note, the authors report one competing interest – their 
engagement in the development of a software tool that will use 
actuarial data to predict LE. This conflict of interest may have lead 
them to interpret subjects’ performance in a poorer light (or 
choose subjects expected to perform poorly). 
Overall external validity (good/fair/poor): Fair - Poor 
The sample size is very small and there is no reporting of subject 
selection, nor of subject demographics. With regard to cancer 
screening decisions, there are no primary care providers included 
in this study.  
The vignettes do appear to represent the types of older adult 
outpatients who would be subject to difficult cancer screening 
decisions, as they include older adults with LE of years to 
decades. Large number and variety of vignettes. 
 
Results 
Mean mortality risk underestimated by 10.8% (range 3.9 to 33.2%) 
--15 physicians predominantly underestimated, while 3 predominantly overestimated 
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Authors point out that clinical significance of this magnitude of error would depend on the guideline guiding the use of 
mortality risk in clinical decision making. Authors note that if a 50% probability of being alive at 10 years were used as 
a threshold for some treatment by this subject group, as many as 34% of vignette patients would be denied treatment 
based on underestimation of LE, and 24% would be inappropriately offered treatment based on overestimation of LE. 
 
Intra-rater reliability: 0.74 (0.31 - 0.94) (no reporting of how this statistic was determined) 
Inter-rater reliability: 0.58 
 
Study citation: Wirth R, Sieber CC. Health care professionals underestimate the mean life expectancy of older 
people. Gerontology. 2012;58(1):56-59. 
Area of potential 
problem 
Internal or External 
Validity? 
Description of potential problems 
Patient Vignette/Assessment Characteristics  
Patient demographics External validity Men and women at age 0, 70, 80, and 90 
Prevalence, severity of 
patient comorbidities 
External validity, 
Internal validity 
No health data given, only age and gender. 
Level of detail of 
vignettes 
External validity Age and gender only. 
Number of patients 
represented 
Internal validity 8 scenarios (both genders at 4 ages); 6 scenarios represent older 
adults 
Choice and Application of Reference Standard for LE (e.g., actuarial LE) 
Appropriateness of 
reference standard 
Internal validity Official life tables for country of Germany, 2007-2009 
(Statistisches Bundesamt: Sterbatefel Deutschland) 
Sophistication of 
reference standard 
Internal validity Relatively unsophisticated. Only accounts for age and gender. 
Clinician recruitment, characteristics 
Sample size of clinicians Internal validity 211 participants start questionnaires; 206 are included in analysis 
--51 physicians 
Subject selection External validity Participants are audience members of the corresponding authors’ 
lectures and seminars (9/2010 – 11/2010) in Germany 
--Per correspondence with the author, the lectures were on 
general medicine topics unrelated to prognostication or LE.  
Clinician characteristics External validity Of 206 participants: 
     --51 (25%) medical doctors (11 geriatricians) 
     --38 (18%) 5
th
-year medical students  
     --77 (38%) nurses 
     --7 (3%) occupational therapists or physiotherapists 
     --33 (16%) other – especially nursing assistants 
For physicians (from raw data provided by study author):  
     --31% male, 59% female, 10% gender missing 
     --Age: 
      
     --Specialty: 12 internal medicine, 11 geriatrics, 10 neurology, 3 
general medicine, 3 surgery, 10 other (have data), 2 missing 
 
Assessment Methods 
Assessment Internal validity, Questionnaires administered during or following lectures and 
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administration External validity seminars and were completed anonymously.  
 
Per personal communication with Dr. Wirth, the subjects were 
recruited during lectures given by Dr. Wirth on general medicine 
topics other than life expectancy. The subjects were not allowed 
to speak to each other or use any resources.  
 
The authors note that, based on their analysis, they are 
concerned that some participants estimated a total LE as high as 
110 years, perhaps reflecting a misunderstanding of the 
instructions not to project extensions of LE in the future but to 
consider LE today. Eliminating participants who made extremely 
high LE predictions from analysis would have made the average 
underestimation of LE more pronounced. 
Overall potential for 
measurement bias 
Internal validity Moderate - high 
Outcomes and Analysis 
Handling of incomplete 
responses 
Internal validity 5 out of the original 211 questionnaires were excluded for 
incompletion. 206 questionnaires are complete for all predictions. 
Other analysis problems Internal validity -- 
Overall internal validity (good/fair/poor): Fair - Poor 
This pilot study reported only brief methods; however, Dr. Wirth 
provided further information in personal correspondence 
suggesting that the surveys were applied fairly. 
Rather than vignettes, the authors simply asked participants to 
determine LE for age & gender groups, without providing any 
health or risk factor information. It is possible or even likely that in 
live patient interactions, information about patients’ health or other 
factors would influence these LE estimates greatly.  
 
Overall external validity (good/fair/poor): Fair  
The subjects are attendees of medical lectures and seminars who 
complied with the questionnaire distributed. Because of their 
interest in these lectures on unknown general medicine topics, the 
subjects may differ systematically from health care staff at large, 
but it is difficult to say how they might differ. 
 
Results 
Per the authors’ report, neither subjects’ age, gender, nor professional group influenced estimation error. 
Raw data for the physician subgroup (n=51) were obtained from the Dr. Rainer Wirth and analyzed by myself in MS 
Excel: 
 
Mean Predicted LE (yrs) Actuarial LE (yrs) Absolute PE (yrs) Std Dev PE (yrs) 
Men 70 y.o. 10.75 13.6 -2.85 3.97 
Women 70 y.o. 14.38 16.4 -2.02 4.34 
Men 80 y.o. 5.37 7.7 -2.33 2.64 
Women 80 y.o. 7.72 9 -1.28 3.41 
Men 90 y.o. 2.65 3.9 -1.25 1.65 
Women 90 y.o. 4.27 4.3 -0.03 2.35 
AVERAGE   -1.63 3.20 
*PE = prediction error  
 
Of note, subjects were also asked to predict LE from birth for males and females. Physicians as a group tended to 
overestimate LE from birth by 4.23 (males) or 3.70 (females) years, although they underestimated the LE of older 
adults. 
 
--Other finding: medical students plus physicians, as a group, estimate LE to be significantly lower than all others, as 
a group (17.6% underestimation vs. 4.4% underestimation; p = 0.003) 
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